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I N T R O D U C T I O N 
CHAPTER 1 A GENERAL INTRODUCTION TO PHARMACOKINETICS 
1.1 Introduction 
It is a commonly accepted theory, that the pharmacological 
effect of a drug depends on the interaction of the drug 
with receptor sites, that are located in the target tissues. 
The intensity of such an effect depends on the degree of 
receptor occupation, which can be related to the drug con-
centration in the direct vicinity of these receptors (the 
biophase), and to the affinity of the drug for the recep-
tor (1). 
In man and in animals, the drug concentration at these 
sites is often very difficult to measure.Since plasma sup-
plies all tissues it is obvious however, that a certain 
(sometimes very complex) relationship must exist between 
the drug concentration in this body-fluid and the concen-
tration in the biophase. 
From the time at which the drug is administered, to the 
time at which it has completely disappeared from the body, 
the plasma concentrations and therefore the tissue concen-
trations change with time.The processes that are respon-
sible for this, are: 1/ absorption of the drug from the 
site of application into plasma; 2/ distribution of the 
drug from the plasma into organs and tissues; 3/ elimina-
tion of the drug through biotransformation (e.g. in the 
liver) or by excretion (e.g. through the kidney). 
After application of the drug, the simultaneous occurrence 
of these processes provides a concentration-time history, 
which is different from drug to drug. 
The main purpose of pharmacokinetics is to describe this 
concentration-time history in plasma and other bodyfluids, 
tissues and excreta,and to construct models, suitable to 
interpret such data (2). 
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Pharmacokinetics also deals with the study of the relation-
ship between the pharmacological activity of drugs or their 
metabolites and their concentration in the various body-
fluids, organs and tissues (3,4), 
1.2 Pharmacokinetic models 
In pharmacokinetics compartmental models are often used as 
a tool to describe the concentration-time curve of drugs 
from the time they are administered, to the time they are 
no longer detectable in the body.In this approach the body 
is assumed to be constituted of one or more connected pools 
(compartments), in which the amount of drug is assumed to 
be homogeneously distributed. The transfer of drug between 
the compartments and the elimination of drug from one or 
more of the compartments are generally assumed to be first-
order processes. In that case the term linear pharmacokin-
etics is used. There are however various cases in which 
elimination processes like renal-excretion or enzymatic-
degradation are capacity limited,and are concentration 
dependent, so that the kinetic description becomes dose de-
pendent. Those cases are referred to as nonlinear-pharmaco-
kinetics (5). 
Although in the real situation, the body consists of a large 
number of compartments (theoretically an infinite number), 
in many cases only a few compartments are necessary to des-
cribe the pharmacokinetic data (mostly plasma levels) ade-
quately. These compartments do not have a direct physiolo-
gical meaning and are rather abstract pools,necessary to 
account for all aspects of the concentration-time profiles. 
For instance in the situation where the elimi-
nation rate of a drug is extremely small as compared to its 
distribution processes, the body can often be considered to 
consist of only one compartment. 
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Fig 1.1 Schematic representation of an open one compartment model 
for intravenous application. 
Figure 1.1 shows a schematic representation of such an open 
one-compartment model, for intravenous application of a drug. 
The rate of elimination of drug from that compartment can 
simply be described as: 
dA1/dt = - CL . C 1 or dC1/dt = - CL/V1 . C^ (1) 
where:dA./dt = the elimination rate (e.g. mg/min) 
CL = the clearance constant (e.g. ml/min) 
V = the volume of the compartment (e.g. ml) 
Obviously the elimination rate is linearly related to the 
concentration. Integration of equation 1, leads to the 
following equation for the concentration С : 
In C 1 = In C1(0) - к .t or C 1 = C1(0).e"
klt ( 2 ) 
where: С (0) = the concentration at t = 0 
k. = the rate-constant for elimination к =CL/V 
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Instead of the rate constant к sometimes its reciprocal, 
the time constant Τ is used. 
From equation 2 it follows,that the logarithm of С de­
creases linearly with time, and the theoretical concentra­
tion-time curves show a linear course when plotted semi-
logarithmically. The biological half-life can be easily 
deduced from this type of curves, and this parameter is 
used in practice to characterize the rate of elimination of 
a certain drug from the body. From equation 2 it follows 
that: 
t, = In 2/k1 = 0.69/k1 (3) 
The volume of distribution V. can be obtained from the in­
tercept of the semi-logarithmic plasma-concentration curve 
at zero time: 
V 1 = D/C1(0) (4) 
where: D = the administered dose of the drug. 
In this model the clearance-constant CL represents the sum 
of clearance constants,representing the various metabolic 
pathways,renal excretion and all other elimination path­
ways (saliva,sweat,bile,lungs). 
In those cases where the distribution of the drug throug­
hout the various tissues in the body is not extremely 
rapid as compared to the elimination process, the semi-
logarithmic concentration-time curves show a bi-, tri-, or 
even more phasic course. Here multicompartmental models have 
to be used to describe the curves obtained. 
In all cases (as long as linear kinetics apply), the gene­
ral equation for C. (concentration of drug in the central 
compartment) will have the following form: 
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С. = E С. (0) e"*!* ( 5 ) 
1
 i=l 
the drug concentration in compartment 1 
the number of compartments 
the concentration at the concentration axis 
(t=0) for the various phases 
the rate constants for the various phases 
The calculation of the various pharmacokinetic parameters 
may be generalized to: 
η 
V, = D/ Ζ С, (0) (6) 
1
 i = l 1 
η 
CL = D/ ¡Γ 1 . С (0) (7) 
i = l j ^ 
v
*
=D/[L ^І 2 'Ci(o) ^ ( ^  ^ 'Ci<0) i<8) 
V. stands for the apparent volume of distribution of the 
α 
drug;or the volume of a hypothetical compartment neces­
sary to contain the amount of drug in the body, if it were 
uniformly present in the same concentration in which it is 
in the central compartment. 
Instead of describing extensively the various models used 
in this approach (for describing e.g. oral absorption) 
reference is made to some excellent standard works on this 
matter (6,7,8,9,10) . 
A useful overall description of the plasma curves of drugs 
is also possible with the aid of the model independent sys­
tem parameters as defined by Van Rossum and Van Ginneken(11). 
where 1 
η = 
^(0) = 
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CL = D/ AOC (9) 
MRT (mean residence time) = AUCT/ AUG (10) 
V. = CL . MRT (11) 
α 
in which : D = dose of drug administered 
AUG = (area under the curve) = 5" с dt 
о 
AUCT =
e
S" t.С dt 
1.3 Physiologically based pharmacokinetic models. 
The main purpose of the development of mathematical phar­
macokinetic models is to be able to describe and predict 
the time course of drug disposition throughout the body. 
The classical approaches as described in the second para­
graph of this chapter, are usually based on the curve-
fitting of plasmalevels with multi-exponential funtions 
to construct the necessary compartment models. 
In most cases, the compartments and the parameters derived 
from such descriptions have no physiological meaning as they 
have no resemblance to the physiological structure or be­
haviour of the animal species under investigation. 
A somewhat different, although certainly related approach, 
has been termed physiological pharmacokinetics. In this 
approach predictive pharmacokinetic models that incorporate 
the known anatomy and physiology of the animals and of man, 
have been receiving increased attention in the recent years. 
Utilisation of known anatomical and phy­
siological functions as a basis for pharmacokinetic models 
was early (1937) proposed by Theorell (12), and later by 
Bellman et al (13) . Bishoff and Brown (14) combined the va­
rious ideas of their predecessors into a comprehensive model 
for drug distribution. 
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In the last few years a variety of physiological-pharmaco-
kinetic models for numerous drugs and in several species 
have been presented.Reference is made to some reviews on 
this matter that have been published (15,16). 
A physiological pharmacokinetic model is generally composed 
of a number of lumped compartments representing organs or 
tissue spaces, whose drug concentrations (like in the clas­
sical models) are assumed to be uniform. These compartments 
are arranged in a flow diagram. As an example figure 1.2 
shows such a diagram. 
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Fig 1.2 Example of a physiological pharmacokinetic model. 
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Differential mass balance equations are written for each 
compartment to describe in-, and out-flow, accumulation or 
disappearance of drug. 
One of the advantages of this kind of models is, that with-
in these models flow-limited and capacity-limited processes 
can be described within the same overall model. Flow-limit-
ed transport occurs for instance when the rate of uptake by 
a tissue is relatively rapid as compared to the bloodflow-
rate. In that case the rate of uptake by that tissue is li-
mited by the rate at which the drug arrives at that tissue. 
There are several reasons which justify the 
development and application of such mathematical models: 
a/ They can provide a rational basis for correlation of ki-
netic and physiological data. 
b/ These models can guide in future experiments»helping to 
find "critical" experiments. 
c/ By predicting blood and tissue concentrations, these mo-
dels can help to guide clinical therapy in a more rational 
way. 
d/ By providing insight into the fundamental mechanisms of 
transport, these models can assist in the problem of extra-
polating results from one animal species to another. 
This kind of models should be able to provide predictions 
of drug concentrations in the tissues in which the effect 
of the drug arises (the target tissues). It is important 
to know the concentration-time history in those tissues, 
which is not always predictable from blood concentrations 
alone. 
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CHAPTER 2 AN INTRODUCTION TO THE STRUCTURE AND 
FUNTION OF THE MAMMALIAN KIDNEY 
2.1 General structure of the kidney 
In vertebrate organisms, the constant composition of the 
"milieu interieur" ,the blood and extracellular fluid,is 
maintained principally by the kidney. This organ acts as to 
maintain a constant osmolarity,constant concentrations of 
the principal cations (Na ,K ) and a constant pH. Further 
it excretes a number of products of metabolism such as 
urea. 
In the resting animal as much as 20 to 25 % of the cardiac 
output flows through the kidneys.Thus the kidneys are able 
to adjust rapidly the composition of the blood and the in-
terstitial fluid. 
On looking at a longitudinal section of the mammalian kid-
ney (see figure 2.1) a number of distinct zones can be dis-
tinguished •The outermost layer is called cortex. Internal 
to the cortex is the medulla, which itself can be subdivi-
ded into inner and outer portions. The outer medulla is a 
richly vascular area usually characterized by radially ar-
ranged stnations, which represent the vascular bundles. 
The inner medulla, on the other hand is more homogeneous 
in appearance and it tapers down to a blunt point, the pa-
pilla, which projects freely into a so called minor calyx. 
These minor calyces project into a number (in the human 
kidney into three) major calyces, which then form the re-
nal pelvis, which is the expansion of the ureter. 
The whole triangular medullary complex is called a renal 
pyramid. The cortex encloses the pyramid both superficial-
ly and on either side,so that each pyramid is separated 
from its neighbours by a mass of cortical tissue (a renal 
column of Bertin). 
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Renal 
рупмМа 
Fig 2.1 A longitudinal section of the mammalian kidney. 
Each pyramid together with all the nephrons that are as­
sociated with it, forms one lobe of the kidney. The blood­
vessels between the lobes are known as interlobal vessels, 
while the bloodvessels demarcating the cortex from the me­
dulla are refered to as arcuate bloodvessels. 
While the rat kidney for example possesses only one such 
lobe (an unilobar kidney), the kidney of the larger ani­
mals and in man possesses a number of such lobes (multi-
lobar kidneys). 
The zonation of the kidney is the result of the arrange­
ment of two components ; namely the nephrons, which are the 
basic units of the kidney,and their associated blood­
vessels. 
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The human kidney possesses some 1-2 million nephrons (the 
dog kidney about half a million). A detailed table showing 
the number of glomeruli found by various authors in a number 
of species is given by Rouiller (17). 
Each nephron begins at the renal corpuscle or Malpighian 
body, which consists of the glomerular tuft of cappillaries. 
enclosed within a Bowmans capsule. Although the term 
"glomerulus" only refers to the knot of cappillaries, the 
whole renal corpuscle is usually called a glomerulus. 
The glomeruli are mainly scattered throughout the cortex. 
The cavity of Bowmans capsule leads straight to the begin-
ning of the proximal convoluted tubule.This has a relative 
thick wall and follows a tortuous course. The terminal por-
tion of the proximal tubule is straight (pars recta), and 
passes directly towards the medulla. As it reaches the me-
dulla, the tubule abruptly narrows down and becomes thin 
walled, marking the beginning of the descending limb of the 
loop of Henle, which passes down through the outer medulla 
and for a variable distance into the inner medulla, where 
it bends sharply back on itself in the form of a hairpin 
loop and begins to ascend again. 
The thin ascending limb of Henle's loop abruptly develops a 
thick wall again at the junction of the inner-,and outer-
medullary zone, and it continues to ascend through the whole 
thickness of the outer medulla (the thick ascending limb of 
the loop of Henle). This thick ascending limb enters the 
cortex and becomes the distale tubule. 
This tubule first passes through the cortex, and finally 
opens into a collecting duct. The beginning of the collec-
ting duct lies in the cortical zone. In passing through the 
medulla towards the papilla, the collecting ducts join 
together and form larger and larger ducts, until they fi-
nally open as ducts of Bellini, near the tip of the pa-
pilla into the pelvis. 
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Each nephron consists of a glomerulus (or more correctly a 
Malpighlan body), which produces the glomerular filtrate. 
This ultra-filtrate then passes into a long tubule, that fi-
nally ends up in a collecting duct. These collecting ducts 
unite with other collecting ducts, to form the large ducts 
of Bellini, which run through the papilla to open near its 
rounded tip into a minor calyx. Figure 2.2 shows a schema-
tica! representation of a nephron. 
thick ascending 
limb of loop 
Fig 2.2 A schematic representation of a nephron. 
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The blood supply to the kidney is functionally rather simi-
lar to that of the lung, in that only a relatively small 
amount of blood is necessary for the nutrition and oxyge-
nation of the organ itself, but a very large volume has to 
pass through the capillary system in order that the blood 
may be processed. Adjustments of the blood composition have 
to be made very rapidly and therefore the distribution of 
blood within the kidney can occur in a matter of seconds. 
A schematic representation of the arrangement of the blood 
vessels within the kidney is shown in figure 2.3. 
perforating 
ar tery 
glomerulus 
interlobular a r te ry 
efferent arteriole 
interlobular vein 
efferent arteriole 
arcuate ar tery 
arcuate vein 
medullary plexus 
descending vasa recta 
ascending vasa recta 
outer medulla 
inner medulla 
Fig S.S Diagram to show the arrangement of blood vessels within the 
'kidney. The descending and ascending vasa recta are in fact 
closely intermingled to form vascular bundles in the outer 
medulla, 
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The main renal arteries are relatively large, pass directly 
from the abdominal aorta to the kidneys and have only a 
short course. The veins similarly are relatively short and 
wide, and open directly into the inferior vena cava. 
Once within the kidney the arteries branch out to form a 
number of major branches, which in the smaller animals are 
usually called interlobar arteries.These interlobar arteries 
give branches to the hilar structures, to the capsule and to 
the pelvic mucosa. 
These branches anastomose with the perforating arteries, 
which emerge onto the surface from the interior of the kid-
ney. Thus a proportion of the total renal bloodflow is able 
to pass from the arterial to the venous side, without passing 
through glomeruli or through peritubular plexuses. This 
uncleared blood may explain some of the discrepancies in the 
mearurement of bloodflow through different regions of the 
kidney and the values found for the para-amino-hippuric-
acid clearance (18).The interlobar arteries break up to give 
rise to a number of arcuate arteries, named that way because 
they lie at the junction between cortex and sub-cortex, and 
therefore follow a rather curved course, more ore less para-
llel to the surface of the kidney. From these arcuate arte-
ries themselves a large number of interlobular arteries are 
given off»which give branches that pass directly to the glo-
meruli; the afferent arterioles. Leaving the glomerular tuft, 
the efferent arterioles either pass down into the medulla, 
giving small branches to the capillary plexus of the sub-
cortical zone, and then break up into descending vasa recta, 
or have only a short course, breaking up into a network of 
thin walled peritubular capillaries, which surround the 
neighbouring proximal and distal tubules. 
The cortical capillaries open for the most part directly 
into interlobular veins,twhich end in the arcuate veins. 
The venous drainage of the medulla is mostly by means of 
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the ascending vasa recta. These vessels drain different levels 
of the medullary capillary-plexus and are collected together 
into bundles as they ascend, until they drain into the arcuate 
vessels. The interlobar veins finally unite to form the re-
nal vein, which drains directly into the inferior vena cava. 
2.2 The formation of urine 
Each day about 160 1 of ultrafiltrate are produced by fil-
tration of plasma through the glomerular capillary tufts 
(in the dog of 15 kg about 60 1). The ultrafiltrate is es-
sentially protein free and contains all solutes of small 
molecular dimensions in the same concentration as in the 
aqueous phase of the plasma from which it is formed. 
As the filtrate flows along the proximal convoluted tu-
bules, sodium is actively extruded into the interstitium 
of the cortex. Chloride follows the sodium passively down 
an electrical gradient and water is reabsorbed by osmosis. 
The ions and water deposited in the interstitium are ra-
pidly removed by the blood perfusing the cortical capilla-
ries. Although the volume of the tubular fluid is sharply 
reduced to about 20% of the initial ultrafiltrate by the 
time the end of the proximal tubule is reached, the os-
molar concentration remains unchanged at 300 mOsm/1. 
As the fluid progresses down the descending limb of Henle's 
loop, water diffuses out into the hypertonic interstitium 
of the medulla and the papilla, and sodium diffuses in. 
The volume of the tubular fluid decreases and the osmotic 
pressure increases progressively to the bend of the loop. 
In the ascending limb sodium is extruded into the inter-
stitium. Because the ascending limbs are impermeable to 
water, the osmolar concentration of the tubular fluid is 
reduced. 
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At each level a gradient of about 200 mOsm/1 Is established 
that way between tubular contents and hypertonic intersti-
tium. Indeed it is this capacity of the tubular epithelium 
to establish a modest osmolar gradient at each level, which 
accounts for the much more significant gradient of 300-1200 
mOsm/1, developed along the length of the loop. This proces 
is termed "counter current multiplication" of concentration 
and has been extensively investigated (19,20,21,22). 
The fluid which enters the distal convoluted tubule, is some-
what hypotonie to the surrounding cortical interstitial 
fluid. Its volume is some 15% of that of the initially for-
med ultrafiltrate. 
The extend to which the epithelium of the distal tubule is 
freely permeable to water, depends on the presence of cir-
culating anti-diuretic hormone (ADH).At high levels of this 
hormone, the epithelium of the distal tubules and collec-
ting ducts is freely permeable to water. In that case the 
tubular fluid becomes isotonic with the cortical intersti-
tial fluid, 'by the middle of the distale segment. The active 
extrusion of sodium and the passive osmotic diffusion of wa-
ter continues in the distal tubule, reducing the volume to 
a few percent of the ultrafiltrated quantity, as it enters 
the collecting duct. This fluid becomes progressively con-
centrated as it flows along the collecting duct,giving up 
water to the hypertonic medullary and papillary intersti-
tium.The water which diffuses out of the descending limb 
of Henle's loop and out of the collecting ducts, and the 
sodium which is pumped out of the ascending limb of the loop 
is removed by blood, perfusing the vasa recta of the medulla 
and the papilla. These vessels serve as counter current ex-
changers to reduce excessive loss of osmotical active solutes. 
In water diuresis, in which situation the 
titer of ADH is low, the epithelium of the distale tubule 
and collecting duct is impermeable to water. 
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In that case the hypotonicity of the tubular fluid leaving 
the loop of Henle is maintained throughout the remainder of 
the nephron, and is increased by the continued active extru­
sion of ions, the final urine being diluted and having a 
relative large volume. 
Reference is made to some excellent books, describing kidney 
anatomy and physiology (23,24,25,26,27). 
s% 
4 — active Na* transport 
^ passive Na'diffuslon 
< — passiv« H 2 0 diffusion 
4 * exchange of Na* for κ·,Η·.ΝΗΐ 
inner 
medulla 
Fig 2.4 A sohematia representation of the transport processes of 
water and solutes within the kidney tubule, responsible for 
the formation of urine. The figures in squares represent 
the osmolarity of the various regions of the kidney (товт/Ъ); 
while the figures within the tubule represent the osmolarity 
of the tubular fluid in the various parts of the tubule. 
The percentages indicate the percentage of the volume of 
fluid remaining in the tubular lumen, with respect to the 
volume being filtrated. 
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CHAPTER 3 AIM OF THE INVESTIGATIONS 
Among the various routes over which the living organism 
disposes to eliminate drugs and metabolites, renal excre-
tion is one of the most important pathways. 
Quantification of this route therefore may contribute to 
the planning of correct dosage regimens in pharmaco-therapy. 
In the pharmacokinetic literature an increasing number of 
reports appears, dealing with the interaction of drugs, that 
given in combination interfere with eachothers renal excre-
tion, thereby influencing their mutual kinetic behaviour 
(e.g. 28,29,30,31,32). Quantification of these kinds of in-
teractions may help to avoid possible intoxication caused 
by relative overdosing during chronic medication. Dosage 
regimens also have to be adjusted in cases of impaired renal 
functionning, as reported for example for drugs like genta-
micin or kanamycin (33,34). 
A more quantitative insight into the mechanisms that govern 
the renal excretion of drugs may provide a rational basis 
of dosis adjustment also in those cases, while it may impro-
ve pharmacotherapy in those cases in which therapy is based 
on the interaction of compounds with eachothers excretion 
such as in the treatment of gout, where drugs (e.g. sulfin-
pyrazone,probenecid) are given to enhance the renal clea-
rance of urate (35,36). 
Although much is known about the qualitative aspects of re-
nal handling of drugs, little attention has been paid to the 
quantification of this elimination route. 
We therefore investigated the renal handling of a number 
of compounds (mainly organic anions) in the male Beagle 
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dog, in order to construct models for the quantitative 
description of the various renal excretory processes 
(glomerular filtration, tubular secretion, active-, and 
passive-reabsorption) and possible drug-interaction at 
that level. 
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M A T E R I A L S A N D M E T H O D S 
CHAPTER 4 ANIMAL EXPERIMENTS 
4.1 Introduction 
In order to obtain insight into the quantitative aspects of 
renal excretion, and to conceive models which are able to 
account for these aspects,many samples of plasma and urine 
have to be taken, under strictly controlled experimental 
conditions. This is one of the reasons why we performed our 
experiments in a somewhat larger animal, the male Beagle dog 
instead of in man or in smaller laboratory animals like the 
rat. Another reason for this choice, was the good resemblan-
ce between the human kidney and the dog kidney (1). 
4.2 Materials 
The cannulas used in our experiments were Braunule G-16 
cannulas obtained from B. Braun, Melsungen (G.F.R.), while 
the urine catheters were prepared from tip-trol suction ca-
theters, acquired from Sherwood Medical Industries, Petit 
Rechain (Belgium). DepomycineR (150,000 U procaine-pemcil-
lin-G and 250 mg dihydro-streptomycine base as sulphate per 
ml) was obtained from Gist Brocades, Delft (the Netherlands) 
and sodium pentobarbital from Apharma, Arnhem ( the Nether-
lands) .Inulin and mannitol were acquired from O.P.G., Utrecht 
( the Netherlands).Heparin was obtained from Organon, Oss 
(the Netherlands). All other reagents used were of analyti-
cal grade and were obtained from Merck, Darmstadt (G.F.R.). 
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4.3 Methods 
Male Beagle dogs, weighing from 9 to 15 kg, were used in all 
experiments. The animals were anaesthetized with sodium pen-
to barbital (30 mg/kg). For blood sampling and the applica-
tion of drugs in each of the two forelegs a cannula was in-
serted into the cephalic vein. In order to obtain a suffi-
ciently high and constant urine flow throughout the experi-
ments the dogs received a constant infusion (2-4 ml/min.) 
of a solution containing 5% mannitol and 0.5% inulin during 
each experiment. Inulin was added for measurement of the 
glomerular filtration rate throughout the experiment (see 
chapter 9). In the experiments with salicylic acid, where 
the passive reabsorption of the unionized compound had to be 
minimized , sodium bicarbonate was added as well to the in-
fusion solution. Depending on the infusion rate, the animals 
produced urine at a constant rate of 1-4 ml/min. Also pH 
fluctuations were abolished, the urinary pH ranging from 
6.5-7.4, in the experiments without bicarbonate. 
For the collection of urine samples a double walled urine 
catheter was introduced through the urethra into the bladder. 
At the end of an experiment, the cannulas and the urine ca-
theter were removed, and the dog was allowed to recover. 
Immediately after the experiment, and daily during the sub-
sequent week Depomycine was given intramuscularly as a pro-
tective measure against infections. Treated this way, dogs 
could be used several times for an experiment. Between two 
experiments a recovery period of at least 3 weeks was ob-
served. 
Blood and urine samples were collected at fixed times during 
an experiment, in order to follow plasma concentrations and 
urinary excretion-rates. 
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4.4 Urine and blood sampling 
During clearance experiments it is of crucial importance that 
the amount of drug excreted in urine over a certain period is 
collected quantitatively. To minimize possible errors made, 
when a volume of urine remains in the bladder after a collec-
tion period, at the end of each period (5-10 min.), the blad-
der was rinsed with 15 ml physiological salt solution. In or-
der to prevent variations caused by introducing the catheter 
more or less far into the bladder, the inserted end was per-
forated over a distance of 5 cm. 
Blood samples were drawn from one of the cannulas. To prevent 
coagulation of blood in the cannula this was flushed with 1 
ml physiological salt containing heparin ( 50 UI per ml) af-
ter a sample was taken. 
The blood samples (5-7 ml) were collected in heparimzed tubes. 
After centrifugation for 20 minutes at 2000 g, the plasma 
samples were stored in a deep freezer at -20oC until assay. 
Also the urine samples were stored in a deep freezer at -20oC 
after the pH and the volume of urine voided had been regis-
tered. 
4.5 Results and discussion 
The animal model was used in the renal clearance experiments 
to be described m the following sections. In all cases the 
experimental conditions appeared to be highly reproducible. 
No signs at all were registered of disturbances of the general 
condition of the animals. As judged from the glomerular fil-
tration rate, kidney function was perfectly stable throughout 
the experiments. Also tubular secretion mechanisms remained 
unaffected by the infusion fluids applied. 
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For instance the addition of sodium bicarbonate did not in-
fluence the secretory behaviour of the kidney, with respect 
to the drugs studied. 
The fact that the animals in this method of experimentation 
could be used several times for different clearance studies 
was of crucial importance for our investigations. 
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CHAPTER 5 RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD FOR THE DETERMINATION OF PROBENECID IN 
BIOLOGICAL FLUIDS. 
5.1 Introduction 
In a course of a study on the effect of probenecid (fig. 5.1 
I) on the renal excretion of other drugs we felt the need 
to develop a rapid and sensitive quantitative method for the 
detection of I in plasma and urine. The various older spec-
V f _ 0 > - £ - о - Н I R, = R2 - -СН
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Fig S.l Structural formulae of probenecid (I) and its 
di-ethyl (III and di-iaobutyl (III) analoga. 
trophotometric methods that have been reported (2,3,4) lack 
the required sensitivity and specificity, whereas the more 
recently introduced gas chromatographic procedures (5,6,7,8) 
make derivatization of I necessary, which is a complicating 
and time-consuming step in the analysis. 
In this case high-performance liquid chromatography is the 
method of choice. The procedure described in this chapter 
combines sensitivity and specificity with ease of handling. 
Chromatography is performed in a soap-chromatography mode, 
using a Cg-hydrocarbon stationary phase. As internal stan­
dards the diethyl analog (II) and the diisobutyl analog (III) 
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of probenecid are applied. 
5.2 Materials and methods 
materials 
Probenecid'was obtained from Sigma (St. Louis, Mo.«U.S.A.). 
Compounds II and III were synthesized from p-carboxybenzene-
sulfonylchloride and the appropriate amines, according to a 
procedure adopted from Mieler (9). Stock solutions of I, II 
and III were prepared in 5% sodium bicarbonate. LiChrosorb 
RP-8 (5/лп) and sodium dodecyl sulphate were obtained from 
E. Merck (Darmstadt, G.F.R.). All other reagents were of 
analytical grade. 
agparatus 
The equipment used was a high-pressure liquid Chromatograph 
of Waters Assoc. (Milford, Mass.,U.S.A.) consisting of an 
M6000A pump, a 46K universal injector and a M440 absorbance 
detector. 
A stainless-steel column (15 cm X 0.46 cm I.D.) was packed 
with LiChrosorb RP-8 (5/um).Chromatography was performed in 
a soap chromatography mode using a mobile phase of methanol-
water-acetic acid with 0.005 M sodium dodecyl sulphate ad­
ded as a counter-ion. For plasma samples the mobile phase 
contained methanol-water-acetic acid in a volume ratio of 
49.5: 49.5: 1; for urine samples the ratio was 64.5: 34.5:1. 
The flow-rate was fixed at 1.5 ml/min. 
Some typical examples of chromatograms obtained from plasma 
and urine samples are given in figure 5.2. 
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Fig 5.2 Chromatogram obtained from plasma and urine samples 
a) blano plasma, b) plasma containing compounds I and II 
c) blano urine, dì urine containing compounds I and III. 
extraçtign_groçedure 
Samples of plasma (1.0 ml) or urine (1.0 ml) were trans-
ferred to conical test-tubes, spiked with 1 ml of internal 
standard solution and acidified by the addition of 1 ml 
of 2 N HCl. Extraction was carried out by shaking this mix-
ture mechanically with ethyl acetate (5 ml) for 10 min. 
After centrifugation the ethyl acetate layer was trans-
ferred to another test-tube and evaporated to dryness under 
a stream of dry,filtered air in a waterbath of 45 0C. 
The residue was dissolved in 250 μ\ of methanol, an ali­
quot of which (10 Ml) was injected into the liquid Chroma­
tograph . 
Sàlici äii2D_BI2£§i?y Ее 
Samples of blanc plasma (1.0 ml) or urine (1.0 ml) were 
spiked with various known amounts of probenecid, ranging 
from 0.5 to 40 ug, and with a fixed amount of internal 
standard (usually 25 /лд). Since interfering peaks necessi­
tated different mobile phases for plasma and urine samples, 
optimal chromatographic conditions required different in­
ternal standards. In the case of plasma, compound II was 
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used as internal standard, in the case of urine compound III. 
The calibration samples were extracted as outlined above and 
after injection into the liquid Chromatograph peak height 
ratios of probenecid to internal standard were plotted against 
the amount of probenecid added. 
5.3 Results and discussion. 
Both for probenecid and compounds II and III the efficiency 
of the extraction process was estimated by comparing peak 
heights after injection of standard solutions to peak heights 
obtained after injection of extracted standard solutions. 
The mean recoveries found were 98 +2% (n=6) for probenecid 
and for compound III, and 95 + 2% (n=6) for compound II. 
This recovery appeared to be constant over the concentration 
range 0.5- 40 yug/ml. The detection limit of probenecid with 
the method described was below 0.5/лд/т1, but reproducible 
analytical results were obtained only when the concentration 
was 0.5^лд/т1 or higher. Then the following equations are 
obtained for the calibration graphs from plasma 
С „ ь non!и" 3 · 6 4 х «»«η* compound II X Peak height probenecid probenecid r peak height compound II 
and from urine 
C^^h-, „•*- 0 · 5 6 3 x amount compound III X peakh. probenecid probenecid r peakh. compound III 
Over the whole range studied the standard deviation of the 
plasma and urine determination was 2-5%. 
This method of probenecid analysis was succesfully applied 
to pharmacokinetic studies,details of which will be reported 
elsewhere. As an example of these investigations figure 5.3 
shows the plasma curve obtained after oral administration 
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of a 500 mg dose of probenecid to a human volunteer. 
plasma concentration • 
Ipg mi 109 scaifr > 
TOO η 
probenecid SOOmg oral 
subiect H S 
¿.3 Plasma curve obtained after oral application of a dose о 
500 mg to a human volunteer. 
Although this curve suggests a linear pharmacokinetic pro­
file, experiments with higher doses clearly indicate the 
occurrence of nonlinear, saturable elimination. 
Whereas after a single 500 mg dose plasma concentrations 
are near to the limit of detection at 24 h. after dosing, th 
period may be substantially prolonged after application of 
higher doses. 
Less than 5% of a 500 mg dose is recovered unchanged from 
urine, the rest is metabolised. One of the metabolites is 
the probenecid-acyl-glucuronide (IV, fig.5.4), which can be 
measured in urine after hydrolysis with the aid of /ì-glucu-
ronidase and which accounts for about 25% of the dose. 
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ίΐ^ S.4 Structural formulae of the principal metabolites of pro­
benecid: the aoyl-gluouronide(IV), the вес-hydroxylated 
(V), the carboxyKVI) and the mono-propyl(VII) metabolite. 
For the analysis of the other metabolites (see fig. 5.4) 
some modification of the procedure described above are ne­
cessary. Extraction of these metabolites from urine is pre­
ferably performed with a 5 ml aliquot of a dichloromethane-
diethyl ether (1:2) mixture. As internal standard the die­
thyl analog (compound II) is used. Liquid chromatographic 
separation of the metabolites requires a mobile phase with 
a higher water content than used for probenecid itself. 
By using a mobile phase of methanol-water-acetic acid (39.5: 
59.5: 1) with 0.005 M sodium dodecyl sulphate, the cumulative 
renal excretion of compounds V and VI was found to represent 
about 20% and that of compound VII about 5% of the total 
dose administered. Onder these chromatographic conditions 
compounds V and VI appeared as a single peak in the chro-
matograms, showing a retention time of 5.9 min. The reten­
tion times of compounds VII and II (internal standard)were 
4.5 and 7.7 min., respectively. 
Note¿ 
After the arrival of a Hewlett Packard 1084B HPLC, equip-
ped with an automatic sampling device and a microprocessor, 
it became simple to use peak area ratios instead of peak 
height ratios for the calibrations, 
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For practical reasons,this procedure was preferred for the 
later experiments. 
note_2¿ 
In later animal-experiments, for practical reasons,a dif-
ferent mobile phase than the one described above was used 
succesfully. This phase consisted of a mixture of methanol 
and water (70 : 30).containing 0.01 M tris(hydroxymethyl)-
aminomethane and 0.01 M tetra-butyl-ammoniumhydrogen-
sulphate (obtained from E. Merck, Darmstadt G.F.R.). 
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CHAPTER 6 RAPID DETERMINATION OF RENAL CONTRAST MEDIA IN 
BIOLOGICAL FLUIDS BY MEANS OF HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY. 
6.1 Introduction 
Several iodinated organic acids are very frequently used 
for intravenous urography. The reason for their usefulness 
is the fact that they are rapidly excreted by the kidneys. 
Some of them are excretad solely by glomerular filtration 
but most of them are also secreted via a carrier-mediated 
mechanism in the proximal tubules. 
In the course of a fundamental study on the kinetics of 
urinary excretion of a number of agents, secreted by the 
renal tubules of the mammalian kidney, we needed a rapid, 
sensitive and quantitative method for the detection of some 
contrast media in plasma and urine. Several existing me-
thods, (10,11) lack the required specificity, are laborious 
or need the use of radioactive materials which imposes spe-
cial handling and safety measures. 
The procedure described in this chapter enables the quan-
titative detection of renal contrast media in a simple spe-
cific way, by means of high-performance liquid chromatogra-
phy (HPLC). Although developed for iodopyracet (I) and 
iodamide (ID (figure 6.1), the procedure is applicable to 
some other contrast media as well, e.g. metrizoic acid, 
diatrizoic acid, iothalamic acid and acetrizoic acid. 
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Fig 6.1 Structural formulae of iodopyracet(I) and iodamideIII). 
6.2 Experimental 
materials 
Iodopyracet and iodamide were obtained from Dagra (Diemen, 
the Netherlands). LiChrosorb RP-8 (5мт)), tetrabutyl-
аттопішп hydrogen sulphate and tris(hydroxymethyljamino-
methane were obtained from Merck (Darmstadt, G.F.R.). 
All other reagents used were of analytical grade. 
apparatus 
The equipment used was a Waters Assoc. (Milford,MA,U.S.A.) 
high-pressure liquid Chromatograph, consisting of a M 6000A 
pump, a 46K universal injector and a M440 absorbance detector. 
I was detected at 280 nm, whilst II was detected at 254 nm. 
HPLÇ_çonditigns 
A .stainless-steel column (10 X 0.46 cm I.D.) was packed with 
LiChrosorb RP-8 (5дмп). Chromatography was performed using 
a mixture of 85% water and 15% methanol, containing 0.01 M 
tetrabutylammonium hydrogen sulphate and 0.01 M Tris. 
The elution rate was 1.5 ml/min. 
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A typical chromatogram obtained from a plasma sample is shown 
in figure 6.2. 
a b 
1 
II 
4 8 12 О 4 β 12 
timeí m m ) 
Fig 6.2 Chromatograma obtained from a) blana plasma and plasma 
containing iodopyracet(I) and iodamide(II). 
For the determination of I, II was used as an internal 
standard, whilst I was used as an internal standard for the 
determination of II. Standard solutions of the appropriate 
salts were prepared in water. Samples of plasma (1 ml) were 
transferred into a test tube and spiked with 100 *лі of in­
ternal standard solution (500^g/ml). Next 5 ml of methanol 
were added to precipitate the plasma proteins. After cen-
trifugation at 1500 g for 20 min the supernatant was trans­
ferred into another tube and evaporated to dryness under a 
stream of dry filtered air in a water bath at 650C. 
The residue was dissolved in 300 Ml of water-methanol 
(10:90, v/v). After standing for 10 min, 10 Mi of the clear 
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supernatant were injected directly into the liquid Chroma­
tograph. Urine samples were treated in a different way. 
After diluting 100 >л1 of the urine 10 times with mobile 
phase and spiking it with ІОО^лІ of internal standard so­
lution, 10 Ml of the resulting solution were injected into 
the liquid Chromatograph. 
Samples of blanc plasma (1 ml) or urine (0.1 ml) were spiked 
with various known amounts of the compound to be determined. 
After treating the calibration samples as outlined above and 
injecting them into the liquid Chromatograph, peak height 
ratios of compound to internal standard were plotted against 
the amount of compound added. 
6.3 Results and discussion 
Under the conditions employed no interfering substances 
from blanc plasma appear in the chromatogram (fig. 6.2). 
This holds true for urine as well. The procedure described 
can also be used for the assay of other contrast media, 
such as metrizoic acid, diatrizoic acid, iothalamic acid 
and acetrizoic acid. For this last agent it is necessary 
to chang the mobile phase to contain more methanol and 
less water. 
The method involves no extraction, but the deproteinization 
of plasma should be performed carefully in order to obtain 
clear solutions for injection. The residue after the eva­
poration of methanol is not completely free of protein. 
Therefore it is taken up in the water-methanol (10:90) 
mixture, in which the rest of the proteins settles in about 
10 min. During protein precipitation, evaporation and re-
dissolution no significant dissipation of the analysed sub­
stances occurred. Pure methanol should not be used for this 
redissolution, since injection of the pure methanolic so-
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lution causes assymetric peaks of the contrast media. Also 
a mixture with a higher water content is not usefull, since 
the protein remains emulsified. 
Calibration graphs are linear up to concentrations of at 
least ІОО/ілд/ml. For iodopyracet the linearity was checked 
further and appeared to prevail up to ІОООмд/ml. 
The limit of detection of the various compounds is about 
0.2дід/т1 with the procedure described. By small modifica­
tions (less dilution) this limit may still be decreased. 
Over the whole range studied the standard deviations were 
2-4%. 
The method reported here was succesfully applied to phar­
macokinetic studies aimed at describing kinetic drug inter­
actions. As an example of a pilot study for these investi­
gations figure 6.3 shows a plasma and an urinary excretion 
curve obtained after application of an intravenous dose of 
iodopyracet to a male Beagle dog. The plasma curve shows 
three distinct phases, indicating the occurrence of a three-
compartmental model. 
Iodopyracet is recovered almost completely unchanged from 
urine. By careful analysis of plasma and urine kinetics it 
is possible to obtain insight into the mechanisms of renal 
excretion and into the nature of possible drug interactions 
at the level of tubular secretion. 
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Fig 6.3 Tke plasma concentration and the urinary excretion rates 
of iodopyracet as a function of time after intravenous 
application of 1.71 g of the drug to a dog. 
N o t e : 
After the arrival of a Hewlett Packard 1084B HPLC, equipped 
with an automatic sampling device and a microprocessor, it 
became simple to use peak area ratios in stead of peak height 
ratios for the calibrations 
For practical reasons, this procedure was preferred for the 
later experiments. 
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CHAPTER 7 OTHER HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHIC METHODS 
For several other compounds the analysis could be very 
adequately performed by using liquid chromatographic pro-
cedures. In view of the ease of sample treatment and oï the 
possibility of adapting such procedures to automatic routine 
analysis, whenever possible the HPLC procedures were prefer-
red. 
Materials 
Tetrabutylammonium hydrogen sulphate, LiChrosorb RP-18, 
tris(hydroxymethyl)aminomethane,p-Chloro-Benzoic acid, 
p-Hydroxy-Benzoic acid, p-Nitro-Phenolglucuronide, were 
obtained from Merck (Darmstadt, G.F.R.). 
lodopyracet was obtained from Dagra (Diemen, the Netherlands). 
Salicyluric acid was obtained from Merck (Darmstadt,G.F.R.). 
All other reagents used were of analytical grade. 
7.1 The determination of salicyluric acid in plasma and urine. 
The quantitative determination of salicyluric acid was per-
formed using a high-pressure liquid chromatographic procedure. 
Chromatography was performed on a stainless steel column 
(10 cm X 0.46 cm I.D.) packed with LiChrosorb RP-18 (5длт) 
using as eluent a mixture of 40% methanol and 60% water v/v, 
containing 0.01 M TBA and 0.01 M Tris. The elution rate was 
1.5 ml/min, and p-Chloro-Benzoic acid was used as an inter­
nal standard. The compounds were detected by UV-absorption 
at 254 nm. Under these conditions the retention times of 
Salicyluric acid and p-Chloro-Benzoic acid were 4 and 7 min 
respectively. 
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Samples of plasma (1 ml) were transferred Into a test tube, 
spiked with 100/лі of internal standard solution (500ywg/ml) 
and acidified with 1 ml HCl (2 Ν). Extraction was carried out 
by shaking this mixture mechanically with 5 ml fresly dis­
tilled diethyl-ether for 10 min. After centrifugation for 2 
min at 2000g, the ether layer was transferred into another 
test tube and evaporated to dryness under a stream of dry 
filtered air in a waterbath at 30oC. After the residue was 
redissolved in 200 длі methanol, 300 Ml of the eluent solu­
tion was added and an aliquot (ІОДіІ) of the obtained solu­
tion was injected into the liquid chromatagraph. 
The liquid Chromatograph we used was a Hewlett Packard HP 
10Θ0 В Chromatograph, equipped with an automatic sampling 
device and a microprocessor for measurement of peak areas. 
To 20fAl of the urine samples 100yul of internal standard -
solution and 400 yi.\l of the eluent solution were added, after 
which 10 Ml samples were injected directly into the liquid 
Chromatograph. 
Calibration was performed, using peak area ratios of sali­
cyluric acid to internal standard, after spiking samples of 
blanc plasma and urine with various known amounts of sali­
cyluric acid, and treating them as outlined above. 
In this way linear calibration curves were obtained in all 
cases. 
7.2 Determination of paracetamol-glucurcnlde in plasma and 
urine in the presence of paracetamol 
Por the quantitative dtermination of paracetamol-glucuronide 
a rapid and sensitive HPLC method was developed. 
The Chromatograph used was a Hewlett Packard HP 1080 В 
Chromatograph, equipped with an automatic sampling device 
and a microprocessor. 
A stainless steel column ( 15. cm X 0.46 cm I.D.) was packed 
with 
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LiChrosorb RP-18 ( 5 yum). Chromatography was performed using 
a mixture of 5% methanol and 95% water (ν/ν), containing 
0.01 M TPA and 0.01 M Tris. The elution rate was 1 ml/min. 
The compounds were detected using their UV-absorbance at 254 
nm. 
Samples of plasma (1 ml) were transferred into a test tube 
and spiked with 100 д^ І of internal standard solution (50yug/ 
ml). Subsequently 5 ml of methanol were added to precipitate 
the plasma proteins. After centrifugation at 2000g for 20 min 
the supernatant was transferred into another test tube and 
evaporated to dryness under a stream of dry filtered air in 
a waterbath at 550C. The residue was dissolved in 600 ul of 
mobile phase, an aliquot of which (ІОДлІ) was injected into 
the liquid Chromatograph. A typical chromatogram of a plasma 
sample containing paracetamol, paracetamol-glucuronide and 
the internal standard (4-OH-Benzoic acid) is shown in figure 
7.1. 
Urine samples were treated in a different way. After diluting 
50 Ml of urine 20 times with mobile phase, and spiking the 
diluted sample with 100 Ml of internal standard solution, ІОДлІ 
of the resulting solution were injected directly into the 
liquid Chromatograph. 
Calibration was performed by spiking samples of blanc plasma 
and urine with various known amounts of paracetamol-glucu­
ronide (isolated from rabbit urine, see chapter 8.5), and 
treating them as outlined above. 
Peak area ratios of glucuronide to Internal standard were 
used in the calibration. Linear calibration graphs were 
obtained this way in all cases. 
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Fig 7.1 Chromatogram obtained from plasma containing 4-OH-benzoio acid 
(IS), paracetamol (Pi and paracetamol-glucuronide (G). 
7.3 The determination of p-nitro-phenolglucuronide in 
plasma and urine 
The determination op p-nitro-phenolglucuronide was perfor­
med analogous to the HPLC method described in the previous 
paragraph. As an internal standard lodopyracet was used, while 
chromatography was performed using a mixture of 25% methanol 
and 75% water (v/v), containing 0.01 M TBA and 0.01 M Tris. 
The elution rate was 1 ml/min, and both compounds were detec­
ted by UV absorption at 280 nm. 
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CHAPTER 8 OTHER GENERAL METHODS 
In this chapter first analytic methods other than via HPLC 
are described. Secondly some other general methods are pre-
sented, such as the procedures applied for measurement of 
binding of drugs to plasma proteins and for the isolation of 
paracetamol-glucuronide from rabbit urine. Finally attention 
is paid to the principles of the computer facilities and 
programming used during the investigations. 
Materials 
Phenolsulfonphtalein, indole-3-acetic acid and lead(II)-
acetate were obtained from Merck, Darmstadt (G.F.R.). 
Amberlite XAD-2 was obtained from British Drug Houses LTD; 
Poole (England),while salicylic acid and paracetamol were 
aqcuired from O.P.G., Utrecht (the Netherlands). 
All other solvents and reagents used were obtained from 
Merck, Darmstadt (G.F.R). 
8.1 Determination of phenolsulfonphtalein in plasma and urine. 
The concentration of phenolsulfonphtalein in plasma was de-
termined according to the method described by Ochwadt and 
Pitts (12). To samples of plasma (0.5 ml), 2 ml of acetone 
was added. The mixture was shaken vigorously and centrifu-
gated in stoppered tubes for 10 min at 2000g. After adding 
0.2 ml of 1 N sodium hydroxyde solution to 2 ml of the clear 
supernatant, absorbance was read at 546 nm. 
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Samples of diluted urine (dilution factor 10-20) could be 
measured directly after the addition of the sodium hydroxyde 
solution. Calibration was performed by spiking samples of 
blanc plasma and urine with various known amounts of phenol-
sulfonphtalein, and treating them as described above. 
Linear calibration graphs were obtained in all cases. Blanc 
values were obtained by taking samples of blanc plasma or 
urine through the whole procedure as described above. 
8.2 Determination of salicylic acid in plasma and urine. 
The quantitative determination of salicylic acid in plasma 
and urine was performed according to a spectrophotofluoro-
metnc method modified after the procedures described by 
Harris and Riegelman and by Rowland and Riegelman (13/14). 
Plasma or urine (usually 0.5-1.0 ml) was acidified with 0.5 
ml 1 N sulphuric acid. After adding 10 ml of diethyl ether, 
which had been saturated with water, the mixture was shaken 
mechanically for 20 min. and then centrifugated. 
One ml of the ether layer was reëxtracted with 5 ml phosphate 
buffer of pH= 7.1, by shaking for 20 min. After centrifuqa-
tion, the ether laver was aspirated and residual ether was 
removed by blowing dry filtered air through the buffer solu-
tion. Following this procedure an average recovery of 97 + 3% 
was obtained. 
The fluorescence of the buffer solution was then measured at 
an activation wavelength of 30 8 nm and an emission wavelength 
of 412 nm. Linear calibration curves were obtained over a 
concentration range up to about 100 mg/l in plasma or urine, 
and even over much wider ranges bv anpropriate dilution of the 
samples. Since at higher salicylate concentrations quenching 
of fluorescence occurs, leading to serious under estimation 
of the actual level о*" salicylate, all samples had to be di­
luted and to be rerreas^ red at least once in order to check 
this concentration rarue. 
54 
8.3 Determination of inulin in plasma and urine 
Inulin was determined according to the method of Heyrovski 
(15). The inulin was hydrolysed to fructose and spectrophoto-
metrically measured after reaction with indole-3-acetic acid 
in concentrated (32%) HCL. Absorbance was read at 515 nm. 
8.4 Measurement of protein binding 
The extend to which drugs were bound to plasma proteins 
was measured by means of centrifugation through Visking 
dialysis tubing. 10 cm pieces of dialysis tubing (flat dia-
meter 10 mm, pore size 24 A) were washed in water for 1 hour. 
Excess of water was removed by wiping. Two ml samples of 
plasma were pipetted into a piece of tubing, which was then 
mounted in a u-shape into a centrifuge tube. 
The water on and in the membrane was removed by centrifu-
gation for 10 min at 1000 g. After transferring the dialysis 
bag to another test tube it was centrifuged again for 60 min 
at 1000 g. The ultrafiltrate (150-200 /Ul) was stored in a 
deep freezer at -20OC until assay. In this way, the reduc-
tion of the volume of the original plasma sample was less 
then 10%, so that only a minor disturbance of the protein 
binding equilibrium in plasma occurred. 
Thus reliable estimates of the percentage of protein bin-
ding in the individual plasma samples could be obtained. 
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8.5 Isolation of paracetamol-glucuronide from rabbit urine. 
Each of three rabbits received a dose of 0.5 g/kg.bodyweight 
paracetamol, given orally as a suspension in 25 ml physio-
logical salt solution. Physiological salt was used in order 
to provide for an adequate urine flow. The 24 hour urine 
fraction from these animals was collected and centrifugated 
for 10 minutes at 2000g. The supernatant was then acidified 
with a few drops of acetic acid until a pH of 4 was reached, 
and subsequently an excess of a saturated lead(II)acetate 
solution was added. 
After centrifugation, the precipitate formed was discarded. 
The supernatant was evaporated under reduced pressure in a 
rotation evaporator at 50oC, and the dark brown, oily resi-
due was brought on an Amberlite XAD-2 column. After elution 
with 1 liter of water to desalt the residue, the column was 
eluted with a water- ethanol mixture (50:50 v/v) and the 
glucuronide fraction was collected. This fraction was eva-
porated again and the residue was brought on another XAD-2 
column for final purification. 
After eluting with a solution of water-ethanol containing 
a gradiënt of 1-5* (v/v) ethanol, the fraction containing 
the glucuronide was collected and evaporated to dryness. 
The white powder obtained after evaporation decomposed at 
its melting point at 200oC, and aqueous solutions had an 
ÜV absorption maximum at 243 nm. 
These physical proporties were in close agreement with 
those reported by Smith (16). The NMR and IR spectra pro-
vided further evidence for the proposed structure,viz. 
paracetamol-glucuronide. 
The urine, and the elution patterns of the columns were 
analysed using HPLC (see chapter 7.2). For the identifi-
cation of the glucuronide peak in the chromatograms, in-
cubations with β -glucuronidase were performed. 
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Using the isolation procedure described above, 1.5 gram of < 
the purified glucuronide was obtained. 
This was used in the animal experiment and as a standard for 
the glucuronide determination in plasma and urine. The iso­
lation procedure described here will be used in future to 
isolate several other glucuronides from urine, in order to 
study their renal excretion behaviour. 
8.6 Computer facilities and programming. 
For the fitting of pharmacokinetic data according to vari­
ous mathematical models, several computer programs have 
been developed in the last decennia e.g. Nonlin (17) and 
Randomsearch (18). The curvefitting program in use at the 
computer centre of the university of Nijmegen was originally 
developed by G. Fast and is called Farmfit (19). 
Most computer fits in this thesis were performed by this 
fitting program, which uses a non-linear regression method 
for fitting the experimental data. The program finds a least 
squares fit to a set of concentrations С(ti) at times tj. to 
a model function Fit) by searching for values of the para­
meters for which the sum of squares (SQ) is minimized. 
so = rgi
2
rc(t1)-F(ti)l
 2
 (1) 
where g^ is the weighting factor of the individual data С(ti). 
The computer simulations performed in this thesis were made, 
using the simulation program CSMP III (Continuous System Mo­
delling Program) supplied by IBM (20) . This program was 
designed to analyse continuous systems, that can be described 
by a set of differential equations, in which time acts as an 
independent variable, on a digital computer. 
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We chose the APL-veraion of this program because of its 
interactive character, allowing the on-line preparation 
and adjustments of models and parameters. 
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section С 
T H E C L A S S I C A L R E N A L 
C L E A R A N C E M O D E L 
CHAPTER 9 THE BASIC MECHANISMS FOR RENAL EXCRETION OF DRUGS. 
9.1 The clearance concept in pharmacokinetics 
One of the most fundamental concepts used in pharmacokinetics 
is the clearance concept. In pharmacokinetics the clearance 
function (CD is defined with respect to the body compartment 
in which the drug concentration is followed, and can be regar­
ded to be simply the proportionality factor between the elimi­
nation rate of the drug from that compartment and the drug 
concentration in that compartment: 
dA/dt = - CL . С (1) 
where: A = the amount of drug in the compartment from which 
the elimination occurs (e.g. uq) 
С = the concentration of drug in the compartment at 
time (t) (e.g. ywg/ml) 
CL = the clearance function (e.g. ml/min) 
Usually for С the plasma concentration is substituted so 
that the corresponding compartment is the first (or central) 
one. The total body clearance of a drug is defined as the sum 
of clearance functions of the processes by which the drug is 
eliminated from the body (e.g. renal excretion, metabolism, 
sweating, etc..) In its most simple form this clearance func­
tion is a constant, but it may become a very complicated 
function of time and/or concentration in those cases where 
non-linear excretion processes govern the rate of elimina­
tion. In this thesis the term clearance refers to the plasma-
clearance, as we measured plasma concentrations of the ad-
ministred drugs. 
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The contribution of urinary excretion to the clearance func­
tion is usually referred to as renal clearance (CLR), and can 
be defined with the following equation: 
RR = CL R . С (2) 
where : RR = renal (urinary) excretion rate (e.g. A^g/min). 
CL R = renal clearance function (e.g. ml/min). 
С --= the plasma concentration of the drug (e.g-ttg/min) . 
As follows from equation 2, the renal clearance function can 
be measured experimentally as the proportionality factor be­
tween the average renal excretion rate over a certain period 
of time and the average plasma concentration measured over 
that period. 
The mammalian kidney has the disposal of at least four dif­
ferent mechanisms to excrete drugs and metabolites into the 
urine : 1/ glomerular filtration, 2/ passive reabsorption, 
3/ tubular secretion and 4/ active reabsorption. 
9.2 Glomerular filtration 
Along with the ultrafiltrate, most drugs present in the plasma 
water are filtrated through the "pores" in the glomerular 
membranes, thereby entering the tubular fluid. There are two 
important limitations to this proces.A/ Extremely large mole­
cules cannot pass through the pores easily, and the largest 
are held back completely. The glomerular membrane behaves as 
as if it is pierced by pores of about 7.5 ran in diameter. 
Inulin (M;W. 5500) passes the pores freely, while larger mo­
lecules like myoglobin (M.W. 17000) pass the pores conside­
rably less easily and serum albumin (M.W. 69000) does'nt reach 
the tubular fluid at all under normal circumstances.B/ Drugs 
bound to plasma proteins are also not able to pass the glo­
merular membrane. 
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9.3 Passive reabsorption 
Theoretically all drugs entering the tubular fluid by glo-
merular filtration can diffuse back from this primary urine 
to the renal blood. The driving force for this mechanism is 
the concentration gradient, which is formed between the tubu-
lar fluid and the renal blood perfusing the tubular system, 
as water diffuses from the tubular fluid, making this fluid 
more and more concentrated. Along this concentration gradient 
drugs that are lipophilic enough to pass the lipid membranes 
of the tubular epithelium can diffuse back passively; this 
proces is generally referred to as passive reabsorption. 
The lipophilicity of the drug determines primarily whether 
it is reabsorbed or not, since the drug has to pass several 
lipid membranes on its way to the renal blood. In fact most 
of the metabolic processes (e.g. oxydation,conjugation) in 
the living organism tend to make the parent drug more polar 
and hence more water soluble, in order to make it more sui-
table for excretion in urine by diminishing the passive 
reabsorption process. 
In case of weak acids and bases, the urinary pH also sub-
stantially influences the passive reabsorption process, since 
only the unionized drug molecule is able to pass through the 
membranes. Alkaline compounds like amphetamines will there-
fore tend to be more readily reabsorbed at high urinary pH (1) 
while organic acids like salicylic acid and probenecid are 
mainly reabsorbed at low urinary pH values (2,3). 
Finally urine flow is an important factor influencing the 
extent to which drugs are reabsorbed. The smaller the urine 
flow (the more water is extracted from the ultrafiltrate on 
its way to the bladder) the larger the concentration gradient 
will be, and the more reabsorption will take place. More de-
tailed examples of passive reabsorption of drugs can be found 
in the literature (4,5,6,7). 
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9.4 Tubular secretion 
The findings of Marshall Jr. and Vickers in 1923 (8) and of 
Marshall Jr. and Crane in 1924 (9) concerning the excretion 
of phenolsulfonphtalein constitute the first cogent evidence 
for tubular secretion of an anion in the vertebrate kidney. 
Twenty-four years later a similar mechanism was discovered 
for organic cations (10,11). 
Since then a wide variety of organic acids and bases is known 
to be transported by these two mechanisms. Some examples are : 
p-aminohippurate (12,13,14), salicylates (15,16), phenol-
sulfonphtalein (17,18,19), salicylurate (20,21), penicillins 
(22,23,24), phenylbutazone (25,26), lodopyracet (27,28) and 
organic bases like histamine (29,30), tetraethyl-ammonium (31) 
and thiamine (32,33). 
The process of active secretion, by which drugs can be trans-
ported against a concentration gradient, has been subjected 
to extensive research. From micropuncture studies (34,35) 
and stopped flow studies (36,37) it can be concluded, that 
both secretory mechanisms are located at the proximal part 
of the tubule. The process (or at least one of the steps in-
volved) is energy dependent and can be blocked by inhibitors 
of metabolic processes like 2,4-dinitro-phenol (38). Although 
the precise transport mechanism has not yet been unraveled, 
it is now generally accepted, that the process is principally 
a carrier-mediated one. An extensive report on the structural 
requirements for organic anions to be transported by this 
mechanism was published by Despopolous (39) , summarizing 
literature and own data on some 150 compounds. Despopolous 
proposed, that all secreted anions are characterized by three 
oxygen or equivalent atoms, spatially related in ways mimi-
cking either of two possible configurations of p-amino-
hippuric acid. Although this model accounts for many of the 
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Compounds known to be secreted, it fails to account for the 
secretion of e.g. lodopyracet, salicylates, phenoxyacetate 
(40) and a number of other substances (41). 
Several recent reports strongly suggest the possibility that 
there is more than one type of carrier involved in the active 
transport mechanism (42,43), each carrier requiring a more 
or less specific structural configuration for a drug molecule 
to be transported.The active transport mechanism can be sa-
turated at high concentrations of drug, obviously because 
the number of carrier molecules is limited, and can be charac-
terized using Michaelis Menten kinetics (44) by a maximum 
transport capacity (Tm) and a dissociation constant for the 
drug-carrier complex (Kij·) . 
Another important phenomenon of this process is its sensi-
tivity towards interaction, when two or more drugs are trans-
ported by the same carrier molecule, thereby influencing each-
others renal excretion rate and hence their fate in the body. 
Numerous reports on the interaction of drugs with respect to 
their tubular secretion have been published (e.g. 45,46,47,48, 
49,50). Special mention is made of probenecid (N,N-di-propyl-
sulfamyl-benzoic acid) because of the central position it has 
occupied in studies, designed to characterize the anion se-
cretion system (51,52,53,54,55,56). This substance, originally 
developed as an inhibitor of penicillin excretion, is known to 
act as an inhibitor of various active anion transport mecha-
nisms (e.g. secretion into bile,urine,saliva) for many drugs. 
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9.5 Active reabsorption 
After being filtrated through the glomerular pores, some 
compounds are actively transported back from the tubular 
fluid to the renal blood. In contrast to passive reabsorption 
the active reabsorption mechanism is saturable and sensitive 
to interaction (57) . Like the tubular secretion mechanism 
it is assumed to be carrier mediated and can be described 
using Michaelis-Menten kinetics. Several drugs are reported 
to be transported by this mechanism (e.g. some amino-acids 
and glucose, 58,59,60,61,62). 
9.6 Bidirectional transport 
A number of drugs is reported to be transported by both 
active transport mechanisms e.g. uric-acid (63) , salicvlic-
acid (64) and meta-hydroxy-benzoic acid (65). 
These compounds show either net secretion or net reabsorp-
tion depending upon the transport characteristics of the drug 
with regard to both processes. 
Experiments which indicate active reabsorptive components 
in the renal excretion of e.g. para-amino-hippuric-acid (66) 
suggest, that bidirectional active transport may be a much 
more general phenomenon than is recognized at present. 
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CHAPTER 10 THE KINETIC DESCRIPTION OF THE URINARY EXCRETION 
OF DRUGS. 
10.1 
A conunon way to depict the relation between urinary excre­
tion rate and the plasma concentration (the renal clearance 
function) is a linear plot of the urinary excretion rate 
against the average plasma concentration over each urine col­
lection period. Depending upon the number of prevailing ex­
cretion mechanisms and the relative magnitude of their con­
tribution to overall excretion, these so called tubular ti­
tration curves may show a number of different patterns. 
The most characteristic patterns are shown in figure 10.1, 
which is based on theoretical model calculations. 
For compounds that undergo solely glomerular filtration 
(e.g. inulin, vitamin-B12, iothalamate) or a combination of 
glomerular filtration and passive reabsorption, the obtained 
curves are linear over the whole concentration range (see 
fig. 10.1 a and b). For these compounds the renal clearance 
function is constant and can be calculated from the slope of 
the curves. Mathematically in this case the renal excretion 
rate can be simply defined as: 
RR = (1 - a) . Q G F . С (3) 
where: RR = renal (urinary) excretion rate (e.g. мд:min). 
a = fraction of the filtrated amount of drug, which 
is reabsorbed passively (0<a<l). 
QGF = glomerular filtration rate of the drug (e.g. m5,/min) 
С = plasma concentration of the drug.(e.g. мд/ml) 
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urinary excretion rate 
plasma cone 
Fig 10.1 Theoretical tubular titration curves for compounds that 
are excreted by a) glomerular filtration, b) glomerular 
filtration and passive reabsorption, с) glomerular 
filtration and tubular secretion, d) glomerular filtra­
tion, tubular secretion and passive reabsorption, 
e) glomerular filtration and active reabsorption, 
f) glomerular filtration, active reabsorption and pas­
sive reabsorption, g) and h) glomerular filtration, 
tubular secretion and active reabsorption. 
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The rate of glomerular filtration of a drug can be calculated 
from: 
Q G F = f . C L l n u l i n (4) 
where: f = the fraction of drug which is not bound to plasma 
proteins (04 f ζ 1). 
CIjinulin = t h e r e n a l clearance of inulin, which is equal 
to the actual glomerular filtration rate, 
since this compound is known to reach the 
urine only through glomerular filtration. 
Inulin is not bound to plasma proteins. 
10.2 
For compounds that are also transported by the tubular se­
cretion mechanism (e.g. p-aminohippuric acid, phenolsulfon-
phtalein), the renal excretion rates exceed the glomerular 
filtration rates of these drugs. At high plasma levels 
(where the secretory mechanism becomes saturated), the tu­
bular titration curves start to bend off, and finally they 
run parallel to the glomerular filtration rate (see fig 10.1c) 
Compounds that are also reabsorbed passively show 
a somewhat more complicated course (see fig 10.1 d) The para­
llelism between tubular titration curve and filtration rate 
is lost. The tubular secretion rates can be described using 
Michaelis Menten kinetics: 
RTS = —^ .
 c
s (5) 
(KT + Cs) 
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where: Rps = the tubular secretion rate (e.g.Mg/min). 
Tm = the maximum transport capacity of the secre­
tion mechanism (e.g.Алд/min). 
Kip = the apparent Michaelis-Menten constant for 
the secretion mechanism (e.g. Алд/ті). 
The concentration term Сц in this formula represents the 
concentration of drug at the site of its transport mechanism, 
but since these concentrations are difficult to access ex­
perimentally, the plasma concentration can be substituted 
instead as a working value. If С would differ more than ne­
gligibly from Cg this would be formally corrected for by a 
simultaneous change in KT, which then obviously has only an 
operational meaning. 
Now the simultaneous occurrence of glomerular filtration, 
tubular secretion and passive reabsorption may be described 
theoretically as: 
Ι
-
" Ί 
RR = il - a). Q G F + Tm '. С (6) (KT + C) 
10.3 
The tubular titration curves for compounds that are active­
ly reabsorbed (e.g. glucose), run below the indicated glo­
merular filtration rate, and eventually, like the curves for 
tubular secretion, start to run parallel to this filtration 
rate (see fig. 10.1 e) as this mechanism becomes saturated. 
A more complicated pattern arises when the drug is reabsor­
bed passively as well (see fig. 10.1 f). 
Theoretically these curves can be described using the same 
kinetic approach as for tubular secretion: 
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RAR = Tmar . C
s
 (7) 
(KAR + CS) 
where: R A R = the active reabsorption rate (e.g. мд/min). 
Tmar= the maximum transport capacity of the reab-
sorption mechanism (e.g. /ілд/min) . 
Cs = the drug concentration at the site of its 
transport mechanism (e.g. yug/ml). 
Кдк = the apparent Michaelis Menten constant. 
For Cg as a working value, the plasma concentration can 
be substituted, like in case of the tubular secretion. 
Obviously in this case the discrepancy between С and Cg may 
be much larger than in case of tubular secretion, since Cg 
for reabsorption will be determined primarily by the luminal 
concentration of the drug. Substitution of С for Cg now un­
doubtedly means that the operational parameter K A R cannot be 
interpreted as a dissociation constant of the drug-carrier 
complex. 
So the combination of glomerular filtration and passive and 
active reabsorption leads to: 
RR = (1 - a) . 
Obviously the assumptions made in deriving equation θ impose 
serious limitations to its validity. Formally this equation 
can easily lead to negative excretion rates, which of course 
is devoid of any functional meaning. 
QQF ~ Troar 
(KAR + С) 
(β) 
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10.4 
Still more complicated tubular titration curves will be 
obtained, when a compound is transported by both active 
transport mechanisms (bidirectional transport). 
Figure 10.1 g and h show two of the possible curves. In g 
the secretory mechanism dominates the curve at low plasma 
levels but is overshadowed at higher plasma concentrations 
by the reabsorption mechanism, which has a larger trans­
port capacity. Figure h shows the opposite situation. 
Non-linearities in protein binding of the compound and fluc­
tuations in urine flow and pH (which are assumed to be con­
stant in the cases described above) may further complicate 
the shape of the curves. 
From a tubular titration curve alone no definite answer can 
be obtained to the question which transport mechanisms con­
stitute to the renal excretion of a drug. For instance as 
one of the mechanisms overshadows the other over the mea­
sured concentration range the obtained curve may seem to be 
composed of only the secretory or reabsorption component, 
or may even be straight in the case that the drug is trans­
ported equally well by both mechanisms. Further studies 
(e.g. interaction studies) will therefore be necessary to 
reveal such phenomena. 
As a first approximation the renal excretion of any drug can 
be described by summing up the contributions of the various 
prevailing transport mechanisms: 
Γ 
RR - (1 - a) . I Сер + Tm - Tmar . С (9) | (KT + C) (KAR + C) 
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10.5 Conclusion 
From the fore going it is obvious however that several of the 
assumptions that are implicit in this equation will limit 
its applicability seriously. 
Despite the fact that several succesful examples of the use 
of this approach in renal clearance studies have been repor-
ted (67,68,69,70,chapter 11) there is a strong need for a new 
type of kinetic modelling with regard to renal drug excretion. 
Attempts in that direction, using a multi-compartment kidney 
model, roughly based on anatomical and physiological features 
are presented in section D. 
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CHAPTER 11 Λ SIMPLE MODEL FOR THE KINETIC PROFILE OF PLAS­
MA CONCENTRATIONS AND URINARY EXCRETION RATES OF 
THE GLUCURONIDES OF PARACETAMOL AND P-NITRO-
PHENOL AFTER INTRAVENOUS APPLICATION IN THE DOG. 
11.1 Abstract 
During the course of a study on the renal excretion of drugs 
a method was developed for the determination of the glucuro-
nides of paracetamol and p-nitro-phenol, and for the isolation 
of paracetamol-glucuronide from the urine of rabbits, which 
had received an oral dose of paracetamol. After removing inter­
fering substances like phosphates and sulphates by precipi-
taion with lead(II)acetate, the glucuronide was purified by 
chromatography on an amberlite XAD-2 column. 
Both glucuronides were determined according to a high perfor­
mance liquid chromatographic method. Chromatography was per­
formed on a column packed with lichrosorb RP-18 and mixtures 
of methanol and water, containing 0.01 M tetra-propyl-, or 
tetra-butyl-ammonium-hydrogen-sulphate and 0.01 M tris(hydro-
xymethyl)amino-methane, were used as eluents. 
These methods were used in a preliminary stuy on the renal 
handling of the two glucuronides in the dog. For both com­
pounds glomerular filtration seems to be the predominant 
transport mechanism in the kidney, while no indications were 
found for active transport of these compounds. 
A simple model is formulated to describe the relation between 
the plasma concentration and the urinary excretion rate of 
these glucuronides. 
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11.2 Introduction 
A wide variety of compounds (e.g. hydroxyl-compounds, 
carboxylic acids and some amino-compounds) commonly undergo 
metabolic conjugation, either with a carbohydrate or an amino 
acid/ before being excreted into bile or urine. The conjuga-
tion reactions make these drugs more hydrophylic and hence 
more suitable for excretion in urine. Among the mammalian 
species the carbohydrate used in these conjugation reactions 
is usually glucuronic acid. 
Relatively little is known about the renal excretory pro-
cesses, that govern the urinary excretion of these glucuro-
nides. For some glucuronides evidence is reported (71,72) 
that they are actively transported by the tubular secretion 
mechanism for anions, and even bidirectional transport was 
found to occur (73).In those studies however, glucuronide 
excretion was measured after application of the parent com-
pounds, and interference of these compounds with the renal 
transport of their own metabolites cannot be excluded. 
Also glucuronide formation in the kidney (74) can lead to 
false interpretations of the relationship between plasma 
concentration and urinary excretion rates, when using this 
experimental set up. In a fundamental study on the renal 
excretion of some glucuronides, we measured plasma levels 
and urinary excretion rates of the glucuronides of parace-
tamol and p-nitro-phenol, after intravenous administration 
of the glucuronides themselves to male Beagle dogs. 
In order to obtain a sufficient amount of paracetamol-glu-
curonide necessary for an experiment, a method was developed 
for isolation of this glucuronide from urine after applica-
tion of paracetamol to rabbits. 
Biosynthesis was chosen because chemical synthesis of glucu-
ronides is very laborious while the yields are extremely low 
(75,76,77). 
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11.3 Materials and methods 
See section B. 
11.4 Results 
Plasma_kinetics¿ 
In a series of experiments the dogs received a dose of para-
cetamol-, or p-nitro-phenol-glucuronide given i.V. as a 5% 
solution in water. As a representative example figure 11.1 
shows the time dependent plasma levels and urinary excretion 
rates of paracetamol-glucuronide. 
Γη one of the experiments with p-nitro-phenol-glucuronide, 
the influence of probenecid on the kinetics of renal excretion 
was studied, by pre-administration of probenecid. The dog 
received a priming dose of 180 mg probenecid (at t=-30), 
followed by a constant intravenous infusion of a solution 
containing 0.5% probenecid at a rate of 7 ml/hr. 
In this way a steady state probenecid concentration of 
133 + 10 mg/1 was maintained throughout the experiment. 
All plasma curves obtained show two distinct phases and can 
be described by a biexponential function of the well known 
form: 
С - C « » ! e 4 ^ + C(0)2 e
- 1
^
 ( 1 0 ) 
where: C(0). = intercept of the two respective phases at the 
conentration axis (e.g. wg/ml). 
С = plasma concentration (e.g. yug/ml). 
k. = rate constants characterizing the slope of 
either of two phases of concentration decay 
(e.g. min ). 
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Fig 11.1 Plasma and urinary excretion rate curvee obtained after 
intravenous administration of 780 mg of paracetamol-
glucuronide to a male beagle dog. 
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As a further characterization of the plasma profile of the 
glucuronides, the following model independent system para­
meters (78) are used: 
Clearance = CL = D/AUC (11) 
Mean residence time = MRT = AUCT/AUC (12) 
where : D = dose of the drug 
AUC = S С dt 
AUCT = S^t.C dt 
After intravenous administration also the volume of distri­
bution V_ may be estimated in a model independent way, as 
D = MRT . Cl. In table 11.1 the various relevant parameters 
obtained after fitting the experimental plasma curves with 
the aid of the non-linear regression program Farmfit (79) 
are listed. 
In our experiments 90-100% of the administred dose of glu-
curonide was recovered unchanged from urine after some 300 
minutes, indicating that as was to be expected urinary ex­
cretion is by far the major route of elimination for both 
glucuronides, when injected intravenously. 
Insight into the relationship between the plasma level of 
the compounds and their urinary excretion rate, is obtain­
ed by a plot of the excretion rate against the average plasma 
concentration over each urine collection period. 
Figure 11.2 shows examples of such plots for paracetamol-
glucuronide and p-nitro-phenol-glucuronide. 
77 
Table 11.1 Values of the parameters describing the plasma kinetics 
of paracetamol-, and p-nitro-phenol-glucuronide, together 
with the measured inulin clearance, after i.v. application 
to dogs. The parameter values were estimated by fitting 
the experimental data according to a linear open two com­
partment model. Values estimated by model independent 
procedures do not differ significantly from those expec­
ted on basis of compartmental analysis. 
subject 
NO 
dose C(0). C(0). CL AUG . MRT 'CL inulin 
(mg) (уідд/ml) (Д»д/т1) (min ) (min ) (ml/min) (ml) Смд.min/ml) (min) (ml/min) 
p-nitro-phenol 
glucuronide 750 
2 p-nitro-phenol _„ 
glucuronide 
p-nitro-phenol ,,. 
glucuronide 
(+probenecid) 
paracetamol-
 7 R n 
glucuronide 
235 
593 
199 
257 
133 0.048 0.0093 39 3337 19135 
224 0.204 0.0114 33 2600 22550 
128 0.045 0.0085 34 3272 19954 
189 0.056 0.0057 
86 38+4 
77 36+3 
97 39+3 
21 3226 37370 155 21+2 
As can be concluded from these plots, the renal clearance 
of both glucuronides is comparable to the measured glomeru-
lar filtration rate. For the calculation of the glomerular 
filtration rate in each experiment the measured inulln clea-
rance was used. 
urinary excretion rate 
(>ig/min) 
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5000-
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urinary excretion rate 
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ISO 200 250 
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Fig 11.2 The relationship between renal excretion rate and the 
plaema oonoentration of a) p-nitro-phenol gluouronide 
with and without probenecid and b) paracetamol gluou-
ronide. Glomerular filtration seems to be the predomi-
nant transport mechanism for both glucuronides, while 
the influence of probenecid is negligible. The solid 
line in both curves indicates the glomerular filtra-
tion rate as calculated from the inulin excretion. 
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11.5 Discussion 
The mammalian kidney has several transport mechanisms for the 
excretion of compounds into urine at its disposal (glomerular 
filtration, active and passive reabsorption and tubular secre-
tion) . The renal clearance of a particular compound can be 
looked upon as the sum of the contributions of each of these 
transport mechanisms. 
From our experiments, performed with two ether-type glucuro-
nides in the dog, no evidence is obtained (see figure 11.2) 
that either p-nitro-phenol-, or paracetamol-glucuronide is 
transported into urine by an active transport mechanism. The 
renal excretion rate of both compounds equals the measured 
glomerular filtration rate in each experiment. 
The inulin clearance was used for estimating the glomerular 
filtration rate. Protein binding was not taken into account 
as both glucuronides were confirmed to show little or no 
binding to plasma proteins. The clearances as calculated 
from the fits also were in close agreement with the measur-
ed inulin clearance (see table 11.1). 
Similar findings were reported for the ether glucuronides 
of tetra-hydro-aldosterone (80) and testosterone (81) . 
A further evidence in favour of the assumption, that glo-
merular filtration is the only transport mechanism for these 
glucuronides into urine, is the fact that probenecid, known 
to inhibit the anion transport in the kidney, does not in-
fluence the renal clearance of p-nitro-phenol-glucuronide 
significantly (see figure 11.2). 
It should be kept in mind however, that this type of tubu-
lar titration curves might also be obtained when a compound 
would be transported equally well by the active secretory 
and active reabsorption over the concentration range mea-
sured (see also chapter 10), and when probenecid would 
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inhxbit both processes equally. For the description of the 
renal handling of these glucuronides however this fully hy­
pothetical case seems rather unlikely and needlessly com­
plicating. The relation between the plasma concentration of 
a drug and its renal excretion rate is best described by 
using the clearance concept. The clearance is simply the 
proportionality factor between excretion rate and plasma 
concentration : 
RR = CL R . С (2) 
where R^ = renal (urinary) excretion rate (e.g.ywg/min). 
CL = renal clearance (e.g. ml/min). 
In the case of both glucuronides studied, glomerular filtra­
tion for all practical purposes is the only mechanism invol­
ved and, since their protein binding is negligible, the 
renal clearance function reduces to a constant glomerular 
filtration rate Q
r
p· So the renal excretion rate as measured 
in our experiments can be adequately described as a function 
of time, with the aid of the following equation: 
Г ~i 
RR = Q G F · ι C ( 0 ) 1 e ~ I c l t + С ( 0 ) 2 е " к 2 Ь (13) 
where C(0) and к are the values obtained from the fits, 
and Q__ is the glomerular filtration rate measured as the 
Of 
inulm clearance (see figure 11.3). 
This simple approach however, fails to describe the urinary 
excretion rates during the first 10-20 minutes after the 
intravenous administration, since in that period no pseudo 
equilibrium exists between plasma concentration and urinary-
excretion rate. This discrepancy is caused by the so called 
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renal delay time (82). 
Incorporation of this renal delay requires more sophisticated 
kinetic modelling as will be shown in the next section. 
urinary excretion r a t e 
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Pig 11.3 A representative example of the experimentally obtained 
plasma and urinary excretion rate ouroes, and the curves 
simulated according to equation 13, using the parameters 
listed in table 11.1. 
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section D 
A D Y N A M I C A L A P P R O A C H T O 
R E N A L C L E A R A N C E K I N E T I C S 
CHAPTER 12 KINETIC MODELLING AND THE RENAL EXCRETION OF 
IODOPYRACET IN THE DOG 
12.1 Introduction 
Renal excretion is one of the major routes of drug and 
metabolite elimination in the living organism. Therefore it 
is useful to quantify the various renal excretory processes 
in order to plan correct dosage regimens in pharmacotherapy. 
In a study on the renal excretion of some organic anions, we 
measured plasma levels and urinary excretion rates of 
lodopyracet in the male beagle dog. In the past, iodopyracet 
was frequently used in medicine as a renal contrast medium. 
It is known to be extremely rapidly excreted in urine by 
means of glomerular filtration and tubular secretion. 
We used iodopyracet as a test substance in a dynamic kidney 
model, designed to describe the renal excretory processes 
in relation to the plasma level of a substance. In our current 
investigations this model is used to quantify the renal ex­
cretion of several other drugs, excreted by the same active 
transport mechanism and also possible drug interactions at 
that level. 
12.2 Materials and methods 
The materials and methods for the animal experiments are 
listed in section В chapter 4. lodopyracet was obtained 
from Dagra NV,Diemen (the Netherlands). All other reagents 
and solvents were of analytical grade; Merck Darmstadt (GFR). 
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The determination of iodopyracet in plasma and urine was 
performed according to a HPLC-method we developed and which 
is described in section В chapter 6 
Inulin was determined using the spectrophotometrical method 
described in section В chapter 8-3. 
The extent to which iodopyracet is bound to plasma proteins 
was measured by ultrafiltration through Visking dialysis 
tubing, as described in section В chapter 8.4. 
The animal preparation and the experimental conditions are 
described in section В chapter 4. 
Computer facilities and programming are shortly described 
in section В chapter 8.6. 
12.3 Results 
Plasma curves 
In a series of experiments the dogs received a dose of iodo­
pyracet given i.v. as a 12.5% solution containing an equi-
molar amount of sodium bicarbonate. Figure 12.1 shows a re­
presentative example of the urinary excretion rate and the 
plasma concentration as a function of time. 
The plasma curves show two or three distinct phases and can 
be mathematically described by an exponential function of 
the well known form: 
0- , "kit 
С = L· C(0), . e 1 (11) 
1=1 1 
in which С = plasma concentration 
C(0)= intercept of the various phases at the con­
centration axis 
ki = rate constants characterizing the slope of 
the various phases. 
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plasmaconc. 
(mg/I ; log scale) 
5 0 0 0 n 
urinary excretion rate 
( m g / m i n ; log scale) 
5 0 
1 0 0 0 -
subject 1 
lodopyracet ¡ v. 
66 m g / k g 
- 10 
100 
0.01 
300 
time (min) 
Fig 12.1 Representative example of the urinary excretion rates 
and the plasma concentrations as a function of time 
after rapid i.v. administration of iodopyracet to a dog. 
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A useful overall description of the plasma profile of iodo-
pyracet Is possible with the model-Independent system para-
meters as defined by Van Rossum and Van Ginneken (1). 
CL (clearance) = D 
AUC 
MRT (mean residence time) 
V (volume of distribution)» CL.MRT (4) 
in which: D = dose of drug administred 
AUC = „S^c dt 
AUCT = ¿Tc.t dt 
In table 12.1 the various relevant parameters obtained after 
i.v. administration of iodopyracet in dogs are listed. The 
parameters were estimated on basis of non-linear regression 
analysis of the experimental data (Farmfit,2). 
In this fitting procedure, data points were weighted according 
to their reciprocal values (which means a constant relative 
weight). On visual inspection, the plasma curves showed two 
or three distinct exponential phases. In any case the good-
ness of the fit as indicated by the sum of weighted squares 
of deviations between observed and predicted concentration 
values was better for the three-exponential fit than for the 
bi-exponential equation. The three-exponential fit however 
was only accepted in those cases were the decrease of the sum 
of weighted square deviations was significant. 
It is obvious that a drug which is cleared mainly by tubular 
secretion will exhibit a capacity limited pharmacokinetic 
behaviour. Therefore not unexpectedly, the non-linearity of 
the plasma kinetics of iodopyracet, caused by saturation of 
its renal excretion mechanism at high plasma levels, is clearly 
demonstrated (table 12.1) by a decrease of V and CL in the 
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(2) 
_ AUCT (3) 
AUC 
îable 12.1 Values of the Parametern deeoribing the ріавпа kinetics of 
iodopyracet, after i.V. application of several doses to dogs. 
The values were estimated by fitting the experimental data 
Tcordmg to a linear open two or three compartment model. 
ace 
exp. 
nr. 
A 
В 
С 
D 
E 
F 
G 
H 
subject 
5 
dose 
mg/kg 
49 
66 
66 
129 
132 
190 
350 
364 
AUC 
тіп.д,д/т1 
4823 
6786 
10650 
17760 
20020 
18420 
61640 
62810 
CL 
ml/min.kg 
10.1 
9.8 
6.2 
7.3 
6.6 
10.4 
4.4 
5.8 
V 
ml/kg 
474 
406 
291 
277 
301 
415 
210 
306 
C(0) 1 
//g/ml 
111 
238 
555 
882 
677 
493 
1547 
1246 
C(0) 2 
д*д/т1 
54 
120 
284 
376 
476 
254 
836 
891 
С(0)з 
/лд/ml 
_ 
5.1 
16.3 
15.4 
31.6 
-
-
-
ki 
min -* 
0.074 
0.150 
0.483 
0.270 
0.408 
0.093 
0.081 
0.139 
k2 
min -* 
0.016 
0.027 
0.039 
0.030 
0.033 
0.019 
0.020 
0.017 
k3 
m m
-
 J-
_ 
0.0069 
0.0072 
0.0079 
0.0082 
-
-
-
MRT 
min 
47 
41 
47 
38 
46 
40 
39 
53 
experiments A and G, in which the dog received low and high 
doses of the drug. 
urinary excretion 
The major elimination route for iodopyracet is urinary ex­
cretion. In our experiments 95-100% of an intravenous dose 
was recovered in urine. An illustrative way to depict the 
relation between plasma level of a drug and its urinary 
excretion rate is a linear plot of the excretion rate against 
the average plasma concentration of each urine collection 
period. As a typical example figure 12.2 shows such a plot 
for iodopyracet in one of the animals. 
urinary excretion rate (mg /min) 
6 0 т 
subject 1 
4 0 -
2 0 -
" G F * R TS 
Δ Δ,Δ-" 
V 
/ 
с^ь 
Â 
ζ 
ι 1 1 ι 1 1 1 1 1 г 
0 200 400 600 800 1000 
plasma cone, (mg/l) 
Fig 12.2 The relationship between the renal (urinary) excretion 
rate and the plasma aonoentration of iodopyracet as 
measured in dog 1 after i.V. injection of a dose of 
350 mg/kg. It is obvious that the curve is the result 
of combined glomerular filtration and tubular secre­
tion. The dotted line connecting the experimental data 
points is a simulation according to the kidney model 
described in fig 12.4, using the parameters of table 12.2 
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At high plasma levels the tubular secretion mechanism becomes 
saturated and the curve starts to run parallel to the glo-
merular filtration rate. As expected in experiments in which 
relatively low doses of lodopyracet were given, no saturation 
of the active transport mechanism was measured. 
The inulin clearance remained constant throughout each experi-
ment, indicating that no functional disturbance of the kidneys 
occurred under the experimental circumstances. The measured 
inulin clearance was used to measure the glomerular filtration 
rate of lodopyracet. Obviously, protein binding has also to 
be taken into account. In fact, the glomerular filtration rate 
of a drug will be the product of inulin clearance and the 
fraction of drug present in the unbound form. 
For lodopyracet this fraction appeared to be 0.8-0.9 all over 
the concentration range studied. No significant or consistent 
variations were observed. Protein bindong is not a variable 
factor m these experiments. 
12.4 Discussion 
As a first approximation the renal clearance of any drug can 
be described by summing up the contributions of the various 
prevailing renal transport mechanisms (see section C, chapter 10) 
There are however various cases in which this approach fails 
to describe the experimental data adequately. 
For instance, when a drug is extremely rapidly excreted by 
the kidneys or is accumulated in some part of the kidney tissue 
before it is excreted into the urine, the assumption that 
there is a constant relationship between plasma concentration 
and the concentration at the site of transport becomes invalid 
and the expressions used to describe active transport and 
passive reabsorption of the drug have to be altered. The 
tubular titration curve of 4-aminohippuric acid (PAH) for 
instance differs clearly from the common Michaelis-Menten 
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kinetics (3), and cannot be described adequately using this 
approach. Simulations performed according to a simple Michaelis 
Menten model with: 
RR = 
in which: Q„_ = rate of glomerular filtration of drug 
(Q„.,= CL. ,. χ free fraction) V WGF inulin 
clearly show (figure 12.3) that the slope of the experimental 
tubular titration curves cannot be simulated using this model 
urinary excretion rate (mg/mm) 
Fig 12. г Theoretical tubular titration curvee simulated according 
to equation 5, with varying values for KT, Tm = 1 ? mg/ 
min QQF - 35 ml/min as compared with an experimental 
titration curve for iodopyracet. It ie virtually impos­
sible to simulate the typical shape of the iodopyracet 
curve by using the simple Michaelis-Menten approach. 
(K,. + С) + Q, GF (5) 
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A plausible explanation for these deviations can be found in the 
extremely rapid tubular secretion of lodopyracet. At relatively 
low plasma levels the drug is almost completely extracted from 
the renal plasma. This high extraction ratio results in a large 
fall in drug concentration at the sites of secretion. 
Under such conditions the usual equilibrium approach is not 
sufficient anymore, since the concentration that determines the 
rate of secretion is no longer simply related to the plasma 
level. The kinetics of secretion may become blood-flow limited. 
In such cases the amount excreted by tubular secretion over a 
period of time At should be calculated as the sum of the amounts 
extracted at various decreasing plasma levels in the various 
more or less distinct subsequent portions of the tubular system. 
On basis of such an integrative approach, Kill (3) 
proposed a mathematical description for the tubular titration 
curve of PAH. By using a Michaelis-Menten type of equation 
describing the secretion rate of PAH from the post glomerular 
capillaries into the tubular fluid, and integrating this equa­
tion between the limits for PAH concentration С and С (1-Е), 
E being the extraction ratio during the passage of the post-
glomerular capillaries, Kill obtained the following implicit 
equation for the rate of tubular secretion: 
RTS 
RTS = T M - QR-V
1
"
 ( 1
 - ifc' ( 6 ) 
in which: !*,„ = the tubular secretion rate (e.g. mg/min) 
T M = the maximum transport capacity (e.g. mg/min) 
Q R = the renal plasma flow (e.g. ml/min) 
С = the plasma concentration (e.g. /лд/ті) 
Kill clearly showed that this equation is superior to the 
equilibrium equation in describing PAH excretion. 
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lodopyracet, like PAH, shows a pronounced tubular secretion, 
its renal clearance approximating the effective renal plasma 
flow (4). The urinary titration curve resembles that of PAH 
and can only be described using Michaelis-Menten kinetics, 
when there is accounted for a decreasing concentration of 
drug in renal plasma. 
Though Kill's approach can be used also in this case to 
describe the relation between plasma concentration and the 
amount secreted by the tubules, this model does not incorporate 
glomerular filtration of the compound. Furthermore, it does 
not account for renal delay. We strongly felt the need for a 
more comprehensive and a more versatile model of renal excre-
tion processes. We therefore conceived a new operational model 
which is based in part on theoretical considerations of Fülgraff 
(5), and which is able to account for the various aspects of 
renal functioning. In this sense it is a functional rather than 
a physiological model. Like Kill's model it accounts for the 
decrease in concentration as the renal plasma perfuses the tubules 
but it simultaneously can describe the other transport com-
partments. In this case a renal plasma and a tubular compartment 
(figure 12.4) . 
Active transport takes place from the renal plasma into the 
tubular compartment. 
The transport processes of the drug can be described by the 
following set of equations: 
η 
Σ 
i=l 
C(0). е-кі (1) 
dAj 
dt 
dA3 
dt 
<QR - Q G F) 
"GF С + 
(Κ,ρ + c2) -
+
 < Q R - Qü > 
(κ
τ
 + c2) 
(7) 
(8) 
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RR = Qu · C3 (9) 
C 2 = A 2 / V 2 (10) 
C3 = A3 / V3 (11) 
in which: 
Qu 
'GF 
the rate at which plasma from the central compartment 
perfuses the kidney tubules. 
the rate of glomerular filtration of the drug into 
the tubular compartment (Q 
GF 
CL ,, χ free fraction) inulin 
Q = the flow of urine into the bladder 
V, = the volume of the renal plasma compartment 
V, = the volume of the tubular compartment 
A-; A, = the amount of drug in the compartments 2 and 3 
С.; C', = the concentration of drug in the compartments 2 and 3 
Q R - Q U 
Fig 12.4 Model fo*· 'the renal excretion of iodopyracet. 
1= central plasvia compartment ; 2= renal plasma compart­
ment ; 3= tubular compartment ; Q
r
p= glomerular filtration 
rate of the compound; Q„= rate at which plasma perfuses 
the kidney tubules ; Q .= urine flow; Tm- maximum transport 
capac ity; К-= Міспаеігг-Мепіеп constant for the tubular 
secretion, of the compound. 
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For the volume of the renal plasma compartment a value of 
10 ml was taken, according to data from Chinard et al.(6). 
The volume of the tubular compartment is found to vary with 
the urine flow (7). Over a whole range of urine flows studied 
the quotient between volume and urine flow was practically 
constant. This quotient represents the total renal delay time, 
and was found to be some 1.5 minutes for several drugs (8). 
In our model also a constant renal delay time of 1.5 min was 
assumed, in which case the volume of the tubular compartment 
can be calculated: 
V 3 = Qy .At (12) 
where Q = mean urine flow andA t is the renal delay time 
On the basis of this model a large number of formal calcu­
lations and simulations have been performed with the aid of 
the APL version of CSMP-III. 
As an example figure 12.2 shows in addition to the experi­
mental data, the curve simulated according to the model. 
Table 12.2 contains a summary of the experiments and the 
values of the parameters estimated by simulation. The esti­
mated values for Q R»T M and К were obtained by trial and 
error adjustment in order to arrive at the best set of para­
meters that satisfies the experimental data. The estimated 
errors in the values for Q R and T M ranged from 5-10%. The 
values obtained for K_ are necessarily crude estimates, 
because since only the narrow concentration range, from the 
point at which the curve begins to deviate from its linear 
course to the point at which T„ is reached, reflects the 
saturation kinetics, few experimental data are available. 
Whether the estimated values of Q_ reflect the rate at which 
plasma perfuses the tubules or is too high a value, depends 
upon the possible contribution of iodopyracet leaking from 
the red blood cells,during the passage of the tubular 
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Table 12.?, Values of the parameters characterizing the renal handling 
of Codopyracet in the dog. §„, Tm and K„ are estimated by 
simulating the experimental data accordt-ng to the model 
described in fig 13.4. For 4% a value of 10 ml was taken 
according to Chinard et al. (в), V¿ being calculated using 
equation 12. The other parameters were experimentally 
measured. 
U^e rate of 
exP· subject d o s e CLinulin fraction mannitol urine flow V V 0 R Τ К 
no.
 J
 infusion 
mg/kg ml/min % ml/min ml/min ml ml тД/min mg/min mg/1 
A l 49 21+ 2 90+ 7 
В 2 66 35+ 4 93+ 2 
G 3 66 23+ 4 81+ 4 
D 4 129 34+ 2 75+ 2 
E 3 132 37+ 5 85+ 5 
F 1 190 36+ 5 89+ 7 
G 1 350 33+ 3 81+ 3 
H 5 364 27+ 5 89+ 3 2.4+ 0.2 1.3+ 0.2 
4, 
4, 
2, 
5. 
3. 
4. 
4. 
 
.8+ 
.0+ 
.8+ 
.0+ 
.8+ 
.6+ 
.0+ 
0, 
0. 
0 
0, 
0 
0 
0, 
 
.2 
.2 
.2 
.2 
.2 
.2 
.2 
.
3, 
2, 
3, 
5. 
3, 
2, 
2, 
.7+ 
.7+ 
.3 + 
'
3± 
. 1 + 
.9 + 
.3+ 
0. 
0. 
0, 
0. 
0. 
0. 
0. 
.4 
.3 
.3 
.5 
.3 
.2 
.3 
10 
10 
10 
10 
10 
10 
10 
10 
6 
4 
5 
8 
5 
4 
4 
2 
89 
153 
98 
118 
95 
121 
100 
130 
30 
17 
25 
15 
20 
20 
io 
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capillaries, to the urinary excretion rate. Experiments designed 
to detect such a contribution show only a small amount of iodo-
pyracet being extracted from the erythrocytes during kidney 
passage (9). This is supported by the fact that the in vivo 
diffusion rates of iodopyracet are small (9) as compared to 
the mean residence time of an erythrocyte in the kidney (10). 
Q , therefore, should be regarded as a measure for the flow 
of plasma perfusing the functional parts of the kidney tubules. 
The kidney model presented in this paper also 
takes account of another complicating factor in renal clea­
rance studies, the so called renal delay time. Urine formed 
from plasma at time t will appear in the bladder at time 
t +At, where At represents the renal delay time. 
Using the single injection technique, rapid changing plasma 
levels, especially during the rapid distribution phase cause 
the measured clearances to be somewhat higher than during 
steady state conditions. The model we use accounts for a 
renal delay time of 1.5 minutes. Therefore influence of rapid 
changing plasma concentrations on the excretory parameters 
are abolished. As the inulin clearance used to calculate Q-_ 
is measured at a fairly constant plasma concentration of inulin, 
there is no influence of the renal delay time on this parameter. 
For this reason the tubular titration curves for iodopyracet 
do not run completely parallel with the indicated glomerular 
filtration rate. 
In extension to the classical Michaelis-Menten model, the 
kidney model presented in this paper is able to describe 
tubular transport in terms of Michaelis-Menten kinetics also 
in those cases where these kinetics become supply limited 
(PAH,iodopyracet). As an example figure 12.5 shows theoretical 
tubular titration curves, demonstrating the effect of varying 
К values on the shape of the simulated curves. 
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As can be seen from this figure, the model describes tubular 
transport adequately in those situations where, as for phenol-
red, the transport mechanism is capacity limited over the 
whole range of concentrations (for high values of К ), while 
it provides for a continuous transition from capacity limited 
at high plasma concentrations to supply limited at low plasma 
concentrations (for low values of KT) for drugs like PAH and 
iodopyracet. 
urinary excretion rate(mg/min)-
40-
200 600 800 
plasma cone.(mg/l) 
Fig 12.6 Theoretical tubular titration curves simulated according 
to the model of fig 12.4 with various values for K-,. 
Tn= IS mg/min; Q
aF= SS ml/min; QR= 153 ml/min; Qv= 2ml/min 
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CHAPTER 13 PLASMA AND URINARY EXCRETION KINETICS OF INULIN 
IN THE BEAGLE DOG 
13.1 Introduction 
Inulin (a polymer of D-fructose,MW 5500) is frequently ysed 
in experiments in which the glomerular filtration rate has 
to be measured, since it fulfills all the necessary criteria 
for use as a pure measure of the glomerular filtration rate. 
It is completely filtrated, it is neither reabsorbed nor 
secreted by the renal tubule, it is inert, not metabolised 
and its administration does not influence renal functioning. 
Estimates of inulin clearance (= glomerular filtration rate) 
provide the basis for a standard of reference, against which 
the routes or mechanisms of excretion of other substances can 
be ascertained. 
In this chapter experiments in the male beagle dog with 
tritiated inulin are described. We used inulin as a test sub­
stance to check the validity of the kidney model described in 
the previous chapter 12. 
13.2 Materials and methods 
General materials are listed in section B, chapter 4. 
H -inulin (specific activity 0.53 Ci/mmol) was obtained from 
the Radiochemical Centre Amersham, Utrecht (the Netherlands). 
ρ 
Instagel was obtained from Packard Benelux ,Brussel (Belgium). 
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The determination of H -inulin in plasma and urine was per­
formed by liquid scintillation counting, using the external 
standard method. Sample preparation consisted of mixing 1 ml 
of plasma or 0.1 ml urine with 5 ml Instagel 
The animal preparation and further experimental conditions 
are described in section B, chapter 4. Instead of an infusion 
of a solution containing 5% mannitol and 0.5% inulin, only 
an infusion of 5% mannitol solution was given. 
The computer facilities and programming have been described 
in section B, chapter 8.6. 
Results 
In a series of experiments, each dog received a dose of 
H -inulin (220 mg, 20MCi), given as a rapid intravenous 
injection of a 2% solution. Plasma samples and samples of 
urine were collected at fixed times throughout the experiments. 
As a representative example, figure 13.1 shows the plasma 
concentration and the urinary excretion rate as a function 
of time m one of the animals. 
Plasma kinetics 
On analysis the plasma curves show a distinct tri-phasic 
course and can thus be described by an exponential function 
of the form: 
3 
С = Σ C(0) . е"кі*· (13) 
ι=1 
in which : С = the plasma concentration 
C(0), = the intercept of the various phases at the 
concentration axis 
к = rate constants characterizing the slope of 
the various phases 
106 
urinary excretion rate-
(>ig/min;log scale) 
I O O O O T DOG 4 
2 2 0 m g H-inulin ¡.v. 
2 0 0 0 
1 0 0 0 -
6 0 0 
4 0 0 
plasma сопс.(дд/тІ;Іод scale) 
2 0 0 n 
2 0 0 
time ( m i n ) 
Fia 13.1 Plaema concentration and urinary excretion rates of 
^H-inulin after rapid i.v. administration in one of 
the dogs. Note the fact that, except for the first 
period after administration the curves show a para­
llel course. 
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Of course these curves can also be characterized by the system 
parameters CL, MRT, V, defined in chapter 12. Table 13.1 
shows the compilation of the values for these parameters ob­
tained after fitting the experimental curves by non-linear 
regression analysis with the aid of the computer program Farmfit. 
Table 13.1 Values of the parameter's describing the plasma kinetics of 
2H-inulin, after i.v. application to dogs. The values were 
estimated by fitting the experimental data according to a 
linear open three compartment model. 
dog 
dose (mg) 
AUC (min./Ag/ml) 
CL (ml/min) 
MRT (mm) 
V (ml) 
C(0) 1 (i\g/ml) 
C(0) 2 (/лд/гаі) 
C(0) 3 (/ug/ml) 
k 1 ( m m
- 1 ) 
k 2 ( m m
- 1 ) 
к, ( m m - ) 
1 
220 
6998 
32 
88.5 
2780 
310 
59.4 
44.2 
0.44 
0.051 
0.0086 
2 
220 
5008 
44 
73.5 
3230 
87.0 
50.4 
40.4 
0.23 
0.058 
0.0107 
3 
220 
3927 
56 
77.6 
4345 
83.8 
26.9 
31.8 
0.28 
0.046 
0.0105 
4 
220 
3690 
60 
67.2 
4004 
84.0 
35.3 
29.0 
0.30 
0.042 
0.0113 
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Urinary excretion 
In all experiments 95-100% of the dose of inulin administered 
was recovered from urine. Theoretically the tubular titration 
curves for inulin should be straight lines with slooes equal 
to the measured plasma clearances in the individual experiments 
since the only elimination mechanism for inulin is glomerular 
filtration. Using the single injection technique however, 
the renal delay time (see chapter 12) causes the curves to 
deviate from their presupposed linear course. 
During the early distribution phase, the measured apparent 
renal clearances tend to be somewhat higher than the plasma 
clearance obtained from the fit of the plasma curves. 
As a representative example figure 13.2 shows a tubular 
titration curve for inulin in one of the dogs. 
urinary excretion rate 
(>ig/min) 
4000 
2000 
DOG4 
220 mg 3 H - inulin i.v. 
Τ 
30 40 
plasma cone, (jig / ml ) 
Fig 13.2 The relationahip between the urinary excretion rate and 
the plasma concentration of inulin ae meaeured in dog 4 
after i.v. adminietration of a done of 220 mg. The drawn 
line connecting the experimental data, ie a simulation 
according to the kidney model described in fig 13.3 
using the parameters listed in table 13.2. 
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13.4 Discussion 
Using the kidney model as described in chapter 12, where the 
kidney is divided into a tubular compartment and a renal 
plasma compartment (see figure 12.4), the tubular titration 
curves for inulin can be described. Figure 13.3 shows a 
schematic representation of the model used in our simulations. 
Ου 
QGF fo QR-Q I QR-QU 
Fig 13.3 Model for the renal excretion of inulin. 1= central-
compartment; 2= renal plasma compartment ; 3= tubular 
compartment ; S
r
j.- glomerular filtration rate; QR-
rate at which plasma perfuses the kidney tubules and 
Q..= urine flow. 
The only transport process for inulin is glomerular filtration, 
so the transport processes from plasma to urine can be described 
by the following set of equations: 
С = Σ . C(0) . . е"кі 
i=l 1 
dA, 
dt QGF С - Qr, 
(13) 
(14) 
А
з / V3 
Q
u ·
 C3 
(11) 
(9) 
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In the same way as in chapter 12, the quotient between the 
the volume of the tubular compartment (V,) and the urine flow 
(Q ), represents the so called renal delay time (At). 
In our simulations this parameter was fixed at 1.5 minutes 
(8). The volume of the tubular compartment, which varies with 
the urine flow (7) can then be calculated from: 
V3 = Qv xAt (12) 
In the case of inulin the value for Q__ can be obtained from 
the plasma curves (Q,,,, = CL) . 
or 
With the aid of the simulation program CSMP-III, the 
experimentally obtained urinary excretion data were simulated 
according to the model as outlined above. The course of the plasma 
curve was described using equation 13.,and the parameter values 
for CIO), and k. as obtained from the fits of the individual 
plasma curves listed in table 13.1 
Figure 13.2 already shows in addition to the experimental data 
the simulated curve in one of the animals. 
Another example of such a simulation together with the ex-
perimental data is shown in figure 13.4 
From these two figures it can be seen, that the model ade-
quately describes the experimentally obtained urinary excretion 
data. Perhaps an even somewhat better result can be obtained 
when the renal delay time is adjusted in the individual 
experiments, but since relatively few data are available during 
the rapid distribution phase, this would be rather speculative. 
Nevertheless, it is obvious that the functional kidney model 
proposed is able to yield a fully satisfactory description 
of even the details of excretion data without any difficulty. 
Ill 
u r i n a r y excretion r a t e 
(μς/ΓΤηη, log scale) 
10000 DOG3 
2 2 0 m g H-mulin ι ν 
1 0 0 0 : 
eoo1 
4 0 0 -
plasma cone ^glm\,tog scale) 
2 0 0 -
i ι 
2 0 0 
t ime (mm) 
Pig IS.4 Simultaneous plasma concentration and urinary excretion 
data of ^H-inulin in a dog after rapid i.V. administra­
tion. The drawn lines are the result of simulations 
according to the model and the parameters indicated in 
the text. The lines confirm the validity of the approach. 
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CHAPTER 14 A KINETIC STUDY ON THE RENAL EXCRETION 
OF SALICYLIC ACID IN THE DOG. 
14.1 Introduction 
This chapter deals with the renal excretion of salicylic 
acid , and its quantification. In attempts to clarify the 
renal mechanisms of salicylate excretion, several reports 
have appeared on this matter, demonstrating the influence 
of e.g. urinaty pH, urine flow, probenecid, PAH and aceta-
zolamide (11,12,13,14) on the renal clearance of salicylates 
in various species, but all of them lack quantification. 
These studies show, that the renal clearance of salicylic 
acid has a very complex nature, involving glomerular 
filtration, tubular secretion and active as well as passive 
reabsorption. 
14.2 Materials and methods 
The materials and methods for the animal experiments are 
listed in section B, chapter 4. Salicylic acid was obtained 
from O.P.G., Utrecht (The Netherlands). All other reagents 
and solvents were of analytical grade; Merck, Darmstadt (G.FiE.). 
Probenecid was obtained from Sigma, St. Louis (Mo. U.S.A.). 
Salicylic acid was detected quantitatively 
using the epectro-fluorometric method as described in section 
B, chapter 8.2. 
Probenecid was determined according to the HPLC-method as 
described in section B, chapter 5. 
The determination of salicyluric acid was performed according 
to the HPLC-method described in section B, chapter 7.1. 
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Inulin was determined using the SDectrophotometrical method 
described in section B, chapter 8.3. 
The extent to which salicylic acid is bound to plasma proteins 
was measured by ultrafiltration through Visking dialysis tu-
bing, as described in section B, chapter 8.4. 
Computer facilities and programming are shortly described 
in section B, chapter 8.6. 
14.3 Results 
In a series of experiments, the dogs received doses of 
salicylic acid, given intravenously as a 5% solution con-
taining an equimolar amount of sodium-bicarbonate. 
In order to study the urinary excretion rate at various 
plasma levels of salicylic acid, during each experiment doses 
of 0.5 gram were applicated 4-5 times at time intervals of 
60 minutes. 
In the experiments performed to study the influence of pro-
benecid on the renal handling of salicylic acid, the same 
quantities of salicylic acid were given as in the control 
experiments, after pre-administration of probenecid. In 
order to maintain a fairly constant plasma concentration of 
probenecid, the dogs received a priming dose of probenecid 
(175 mg in dog 4 and 350 mg in dog 3) given as a 2.5% solution, 
followed by a constant infusion of a solution containing 0.5% 
probenecid at a rate of 5 ml/hr. This way steady state plasma-
concentrations were maintained throughout an experiment. 
Figure 14.1 shows a representative example of the plasma 
levels of salicylic acid and the urinary excretion rates of 
salicylic acid and salicyluric acid as a function of time, 
obtained from one of the experiments. 
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Fig 14,1 Plasma concentrations of salicylic acid, and urinary ex­
cretion rates of salicylic acid and salicyluric acid af­
ter repeated injection of O.S g salicylic acid to a dog. 
115 
The relation between plasma concentration and urinary excre­
tion rate of salicylic acid, shown in figure 14.2 as a linear 
plot of the excretion rate against the average plasma concen­
tration of each urine collection period, resembles more or less 
the curves obtained for glucose (15) . At low plasma concentrations 
the amount of salicylic acid being filtrated, is almost comple­
tely reabsorbed, while at high plasma levels the curves 
start to run parallel to the measured glomerular filtration 
rate (R G F) ι indicating a saturation of the reabsorption mecha­
nism. urinary excretion rate-
(¿ig/mm) 
4000 
3000-
2000-
1000 
400 600 
plasma cone (дд/ті) 
g 14.2 Relationship between urinary excretion rate and the plasma 
concentration of salicylic acid. The drawn line connecting 
the experimental data is a simulation according to the 
kidney iiodel described in fig 14.4, using the parameters 
listed in table 14.1. R
r
-- glomerular filtration rate 
и - „„ν-,..,, „„„г, -t .· - ir ί _... _ R AR active reabsorption rate. 
Since under the applied experimental conditions signi­
ficant changes in urine flow, glomerular filtration rate and 
the fraction of salicylic acid bound to plasma proteins did 
not occur, and the urine pH was kept at a high level in order 
to minimize passive reabsorption (table 14.1), glomerular 
filtration and active reabsorption seem to be the prevailing 
transport mechanisms for salicylic acid in the dog kidney 
under these conditions. 
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14.4 Discussion 
In the experimentally obtained tubular titration curves for 
salicylic acid, the prevailing transport mechanisms seem to 
be glomerular filtration and active reabsorption. Passive 
reabsorption which may become very important at physiological 
urine pH, does not seem to play a significant role in the 
clearance process under the experimental conditions, where 
urine pH was kept at values between 7 and 8, because the 
tubular titration curves run parallel to the measured glo-
merular filtration rate of the drug at high plasma levelg. 
where the reabsorption mechanism becomes saturated. 
The glomerular filtration rate can be calculated from the 
inuline clearance, which then must be corrected for the pro-
tein bound fraction of the drug. For salicylic acid the fraction 
of drug not being bound to plasma proteins was some 40% 
(see table 14.1), being practically constant over the concen-
tration ranges studied in the experiments. 
Tubular secretion of the acid, as reportad by various authors 
(12,14,16,17), mainly at low plasma levels, obviously has a 
rather low transport capacity. This transport mechanism could 
only be detected under rather unphysiological conditions, 
such as very high urine flows (14) , where the reabsorptive 
mechanism is minimized by decreasing the residence time of the 
drug in the renal tubules, or in interaction experiments. 
This secretory component of the renal handling of salicylic 
acid can also be masked by another complicating factor in renal 
clearance studies, viz. the possible interference of kidney 
metabolism of a drug. In our case glycine conjugation of the 
salicylic acid to salicyluric acid is reported for the dog 
to take place mainly in the kidney (18), and this metabolism 
could possibly mask the secretory mechanism by metabolizing 
the salicylic acid, which is secreted from the renal blood 
into the renal tissue 
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Likewise variations in the rate of metabolism could theore­
tically affect the shape of the tubular titration curves, 
when metabolism appears to be the rate limiting step in the 
reabsorption mechanism. 
The salicyluric acid excretion measured in our experiments 
ranged from 20-60 мд/min, and was practically constant 
throughout an experiment (see figure 14.1), indicating a 
constant rate of kidney metabolism if this would occur at all. 
Such a rate of metabolism is far to small to be responsible 
for the rate at which salicylic acid is removed from the 
tubular fluid after being filtrated through the glomerular 
membranes. 
Like for lodopyracet (see chapterl2), the experimentally 
obtained curves for salicylic acid cannot be described 
adequately using the simple Michaelis-Menten model with: 
τ "I 
R = Q - M ' . С (16) 
G F
 <
KAR + C> 
in which : RR = urinary excretion rate 
QG_ = glomerular filtration rate 
T., = maximum transport capacity of the reabsorption 
mechanism 
K-„ = Michaelis-Menten constant AR 
С = plasma concentration of the drug 
Simulations performed according to this model clearly show 
(see figure 14.3), that the course of the experimental tubu­
lar titration curves cannot be simulated using this model, 
since this model cannot account for the very small splay 
in the curves. One of the most tedious limitations of the 
model is, that the value of Τ,,/Κ maximally can be equal 
to the value of Q
rF> for otherwise negative values for R_ 
will be obtained at low values for C. 
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Fig 14. ζ Theoretical tubular titration curves simulated according 
to equation 16, uith varying values for Tm and К 
The values for K.R are the minimal acceptable vaTues (see discussion). QGp= 20 ml/min.The simulations are 
compared with an experimental tubular titration curve 
for salicylic acid. It is virtually impossible to simu­
late the typical shape of the salicylic acid curve by 
using the simple Michaelis—Menten approach. 
In figure 14.3 the minimal acceptable values for K,,, are 
chosen in the simulated curves; larger values for this para­
meter result in a still larger splay of the simulated curves. 
At low plasma concentrations the reab-
sorptive mechanism for salicylic acid clearly becomes supply 
limited. Analogous to iodopyracet under such conditions the 
usual equilibrium approach is not sufficient anymore, since 
the concentration that determines the rate of active reab-
sorption is no longer simply related to the plasma level. 
We therefore conceived an operational model, like the model 
we used for the description of the tubular titration curves 
for iodopyracet, to describe the kinetics of renal excretion 
for salicylic acid. 
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Figure 14.4 shows a schematical representation of the model 
we used in our simulations. The model consists of a renal 
plasma compartment and a tubular compartment. Active trans­
port takes place from the tubular compartment into the renal 
plasma compartment. 
l R
 QR-QGF 
Tm 
(KAR.C3) 
> 
OR-Qu 
74'. ί Model for the renal excretion of salicylic acid. 
2= central compartment, 2= renal plasma compartment ; 
3= tubular compartment ; Q
r
p= glomerular filtration rate 
Q ~ rate at which plasma perfuses the kidney tubules ; 
Tn= maximum transport capacity ; K.R
=
 Michaelis-Menten 
constant for the active reabsorption process. 
The transport processes of the drug can be described by the 
following set of equations: 
dA, Τ 
d ^ = <QR - QGF' • C + (К,Л С,) 
dA, 
— ^ = О С -
 τ
Μ 
AR 3' 
+ Qn · c
n 
•
 C3 - ( Q R -
 Q ü ) · C2 ( 1 7 ) 
AR 3' 
R
R = Qu · с з 
C 2 = A 2 / V2 
с
з -
 A3 / V3 
(18) 
(9) 
(10) 
(11) 
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in which: 
Q = the rate at which plasma from the central compartment 
perfuses the kidney tubules 
Q = the rate of glomerular filtration of the drug into the 
tubular compartment (Q„_ = CL. ... χ free fraction) 
(jF inUlln 
Q = the flow of urine into the bladder 
V, = the volume of the renal plasma compartment 
V, = the volume of the tubular compartment 
A.;A,= the amount of drug in compartments 2 and 3 
С - the plasma concentration of the drug 
C7;C,= the concentration of drug in compartments 2 and 3 
T M = the maximum transport capacity of the active reabsorption 
mechanism 
К
дв
= the Michaelis-Menten constant for the active reabsorption 
mechanism 
For the volume of the renal plasma compartment a value of 10 ml 
was taken according to data from Chinard et al. (6). The volume 
of the tubular compartment was found to vary with the urine flow 
(7).Over a whole range of arine flows studied, the ratio between 
volume and urine flow was practically constante 1.5 minutes), 
and represented the total renal delay time. 
In our model also a constant ranal delay time of 1.5 minutes 
was assumed, in which case the volume of the tubular compartment 
can be calculated as : 
V3 = Qy xAt (12) 
For Q_ a value of 11 ml/min.kg was taken after B.H. Ewald (19) 
In our experiments the urinary 
excretion data were measured at steady state plasma levels 
during each urine collection period. In that special case, 
where С can assumed to be constant, over a urine collection 
period, the renal delay time does not influence the rela­
tion between plasma concentration and urinary excretion rate, 
121 
and the general model can be simplified. 
In the equilibrimi! situation dA,/dt = 0, so 
Τ M 
Q_p . С - . С, = 0 (19) 
(KAR + СЭ> 
From equation (6) it follows that C, = R / Q 
By substitution, the following relationship between С and R 
can be obtained: 
С = 
Τ R 
+
 Q„ · Я ^ (20) (KAR + V ϋ ' QGF » QU 
The experimental data were fitted according to this equation 
using the curve fitting program NONLIN (20). 
Table 14.1 contains a summary of the experiments and the 
values of the parameters as estimated by NONLIN. 
The influence of probenecid on the renal handling of salicylic 
acid was measured in two experiments. As can be seen from 
table 14.1, probenecid competitively inhibits the active 
reabsorption mechanism of salicylic acid , as indicated by a 
large increase in the value of К _ as compared to the control 
experiments. 
The interaction experiments also reveal the secretory component 
in the excretion pattern of salicylic acid. Probenecid inhibits 
this secretory component as can be concluded from the increase 
of the value obtained for Τ , which obviously must be regarded 
as the sum of the maximum transport capacities of both the 
secretory and reabsorbtive mechanism. 
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Table 14.1 Values of the parameters characterizing the renal handling 
of aalicylic acid in the dog. CI>inulin' ®Ц' */Γββ* probe­
necid cone, and urine pH vere experimentally measured. 
Tm and X4«y uere estimated by aimulating the experimental 
data according to equation 20. 
dog experiment CL inulin 
(ml/min) 
free 
(rtl/min) 
1.0 + 0 . 3 
0 . 9 + 0 . 3 
1.1 + 0 . 2 
1.2 • 0 . 3 
1.1 + 0 . 2 
1 .1 + 0 . 2 
40 + 7 
41 + 6 
45 + 8 
40 + 6 
39 + 5 
41 + 7 
(mg/1) 
-
-
-
52 + 8 
-
110 + 16 
probenecid T„ K„„ urine 
cone.
 M A R
 pH 
(/Ag/min) (mg/1) 
1 salicylic acid 
2 salicylic acid 
3 salicylic acid 
3 salicylic acid 
+ probenecid 
4 salicylic acid 
4 salicylic acid 
+ probenecid 
49 + 5 
35 + 3 
34 + 3 
28 + 3 
53 + 5 
58 + 6 
4600 + 200 27 + 14 6.5 + 0.4 
3700 + 400 20 + 11 7.0 + 0.5 
4300 + 300 32 + 13 7.3 + 0.5 
4900 + 200 148+ 21 7.0 + 0.3 
3100 + 300 51 + 53 7.6 + 0.3 
4000 + 130 179+ 24 7.7 + 0.2 
Urine flow dependency: 
One of the criteria used to reveal passive reabsorption processes 
for drugs, is the Influence of urine flow on the measured renal 
clearances (see section C, chapter 9). 
As for the passive reabsorption mechanism, the transport rate 
of the active reabsorption mechanism depends on the concen­
tration of drug in the tubular fluid, so the latter mechanism 
also shows flow dependency. 
This phenomenon of the influence of Q on the renal clearance 
af drugs transported by the active reabsorption mechanism can 
also be seen on looking at equation (20) , where one of the 
variables determining the renal excretion rate is the urine flow. 
Figure 14.5 shows the influence of Q.. on 
the renal clearance of such a drug, as calculated from equation 
(20) for a number of concentrations C. 
At very high concentrations, where the transport mechanism is 
saturated and its contribution to the renal clearance function 
becomes less and less important, the influence of the urine flow 
dissappears. This urine flow dependency also makes the analysis 
of these kinds of tubular titration curves according to the 
classical model (which does not account for this effect) 
difficult,since urine flow variations between experiments with 
the same drug, would affect the estimated values of К . 
In the dynamical model such effects are incorporated, so that 
the disturbing factors are taken into account. 
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Fig 14.5 TbeoTetioal curves for the relationship between renal 
clearance and the urine flow for various plasma concen­
trations of salicylic acid, simulated according to 
equation 20. 
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CHAPTER 15 KINETIC MODELLING AND THE PASSIVE REABSORPTION 
OF DRUGS 
15.1 Introduction 
As already mentionned in section C, chapter 9.3, passive 
reabsorption of drug from the tubular fluid back to the renal 
blood, depends upon several factors (e.g. lipophilicity of the 
drug, pK -value when the drug is a weak base or acid, urinary 
pH and urine flow). In the classical clearance model as described 
in section C, chapter 10, the passive reabsorption rate simply 
is regarded as the fraction a of the total amount of drug trans-
ported into the tubular fluid, which is reabsorbed. 
This model however does not account for the influences of 
urinary pH and urine flow on the clearances of weak acids and bases. 
The major problem in quantificating these effects using the 
classical approach is the impossibility of accesing the rela-
tionship between plasma levels and the concentration gradient 
between tubular fluid and renal blood, which is the actual 
driving force of the process. 
Within the dynamical model described in section D, in which 
the kidney is divided into a tubular compartment and a renal 
plasma compartment, an operational estimate of this concentra-
tion gradient is obtained in relation to the plasma level. 
The passive reabsorption process can be allocated to the 
tubular compartment (see figure 15.1), and can be described 
using Ficks law of diffusion; 
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Q G F fo QW-QGF 
3
 KpRtCr^ 
Ou 
I 
Q R - Q « 
Fij 16.2 Model for the description of passive reabeorption. 
1= central compartment; 2= renal· plasma compartment; 
3= tubular compartment; QrF= glomerular filtration rate; Qfí= rate at which plasma perfuses the kidney tubules ; Qj.= urine flow; K-p„= constant for the passive reabeorp-
tion process. 
HvT PR ( c3 - c2 ) (21) 
in which: 
IU = the passive reabsorption rate (e.g.Ллд/тіп) 
k O D = a constant for the reabsorption process P R
 (e.g. ml/min) 
- C-= the operational concentration gradient 
(e.g. yug/ml) 
In the situation where a drug is filtrated in the glomeruli 
and then passively reabsorbed from the tubular compartment, 
the following equations govern the transport of drug in and 
out of the various compartments : 
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dìT " (QR - QGF) · C + kPR-(C3 - «V - (QR - %> • C2 W 
dA, 
är = QGF · C - kPR-(C3 - «V - Q« · С З ( 2 3 ) 
RR = Qu · C3 (9) 
Under steady state conditions where dA./ddt and dA./dt are 
zero, these equations can be combined to: 
CLB = Rn/C =
 (QGF-QR + kPR-0R ' QGF-QU) · ^ U 
A further simplification can be made when the urine flow (Q
n
) 
is small as compared to the renal plasma flow (Q ).In that 
case equation (24) can be reduced to: 
. ' v - 4.' • % 
R KPR U0 
While for very high values of Q equation (24), as expected 
approaches the glomerular filtration rate (Q_„). 
Figure 15.2 shows as an example the flow dependent clearances 
for a number of values for к . 
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Fig 15.2 Theoretical curvee for the relationehip between renal 
clearance and the urine flow, simulated according to 
equation 24 for various values of Κ
τ 
"PR· 
15.2 The influence of urinary pH 
In the case of weak acids or bases, only the unionized 
fraction of drug is capable of traversing the lipid membranes 
and the actual driving force for reabsorption is the con­
centration gradient of unionized drug between tubular fluid 
and renal blood. 
The unionized fraction (oc) of drug, for instance a weak acid, 
in a fluid can be calculated using the Henderson-Hasselbalch 
equation: 
ΓΑ^ Ι 
pH - pK
a
 = log
 l H k 2 
where:^ CHA] 
ГА"5 + CHA] (iopH"pKa + η 
(26) 
(27) 
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In case of a weak acid that is transported by glomerular 
filtration and passive reabsorption, the equations (22) and 
(23) can be adjusted: 
dA 
IT - ( Q R - QGF ) « C + k P R - ( C V C 3 - V ' V - (QR - %) • C 2 ( 2 β ) 
dA, 
IT = Q G F ·
 C
 -
 kPR· ' V C 3 - "і-Ч - QU · C 3 ( 2 9 ) 
RR = Ou · C 3 ( 9 ) 
where: W, = fraction of unionized drug in the tubular compartment 
CX.2 = fraction of unionized drug in the renal plasma 
compartment 
Under steady state conditions these equations can be combined 
to: 
C L
 (QGF-QR + " P R - V Q R - Q G F - V · QU
 (з 0 ) 
R =
 Qü-(kPRÄ2 + QR- W + ^ -«з-^рн^г + QR-Qü) - ^ - ^ г ^ з 
As an example figure 15.3 shows the relationship between 
urinary pH and clearance 
for various urine flows . 
for a hypothetical weak acid (pK =4) 
15.3 Discussion 
In contradiction with the classical renal clearance model, 
the dynamical model is able to account for influences of 
urine flow and/ or urine pH, on the renal clearance of 
substances that are reabsorbed passively from the tubular 
fluid, after being filtrated by the glomeruli. 
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Fig 1S.3 Theoretical curves for the relationship between renal 
clearance and urinary pH for a hypothetical weak acid 
simulated according equation SO for a number of values 
for Q
u
; pK
a
=4. 
The simulated curves illustrating the influence of these 
variables, are reported in various papers (21,22), in which 
these influences are described qualitatively. 
The proposed model provides for a quantitative description 
of these phenomena, and generates operational parameters, 
for the characterization of these processes. 
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section E 
S I M U L T A N E O U S D E S C R I P T I O N O F 
P L A S M A L E V E L S A N D U R I N A R Y 
E X C R E T I O N R A T E S O F D R U G S A N D 
T H E I N F L U E N C E O F P R O B E N E C I D 
CHAPTER 16 DRUG INTERACTION AND THE REHAL EXCRETION 
OF DRUGS 
16.1 Introduction 
Today there is much concern about "drug interactions", because 
a growing number of patients receive more than one drug at 
a time, and doctors are not seldom unaware of the risks to 
which their patients are exposed, when treating them with 
more than one drug. 
Investigations performed on the incidence of drug-induced 
adverse effects in patients (1,2), show, that there is a 
significant correlation with adverse effects and multiple 
drug therapy. 
There are many possible sites of drug interaction: 
a/ in the intestine , drugs may influence eachothers reab-
sorption 
b/ at the plasma and receptor binding sites, drugs may 
compete for binding 
c/ at the drug-metabolizing enzymes, drugs may interfere 
with eachothers metabolism 
d/ at the excretory mechanisms, drugs may interfere with 
eachothers excretion 
Since most drugs pass through, and are eliminated by the 
kidneys, this is obviously a very fruitful site for drug 
interactions to occur. 
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16.2 Drug interactions in renal excretion 
Drugs may interfere with eachotherd renal transport mechanisms. 
For instance with eachothers glomerular filtration rate, when 
the given drugs show competition for binding to plasma proteins, 
(3,4). The passive reabsorption mechanism of weak acids and 
bases also is sensitive to interaction phenomena, for instance 
drugs that enhance the urine pH (e.g. sodium-bicarbonate) or 
urine flow (e.g. diuretics) influence the excretion of weak 
acids or bases,like amfetamines (5). 
Another important interaction can be the interference of drugs 
with respect to the tubular secretion mechanism. A classical 
example is the interaction between penicillin and probenecid. 
Probenecid is known to inhibit various active transport 
mechanisms of drugs, thereby influencing their fate in the 
living organism. In case of penicillin, it for instance pro-
longs the biological halflife of these antibiotics ,by re-
ducing their renal excretion (through interaction with the 
secretory mechanism of these compounds) (6,7,8) 
An example of drug interaction with respect to the active 
reabsorption mechanism is found in the pharmaco-therapy of 
gout, where probenecid reduces the urate level in the body 
by increasing the renal clearance of that compound (9), via 
inhibition of the active reabsorption. 
137 
CHAPTER 17 SIMULTANEOUS KINETIC MODELLING OF PLASMA LEVELS 
AND URINARY EXCRETION OF SALICYLURIC ACID, AND 
THE INFLUENCE OF PROBENECID 
17.1 Introduction 
In the last few years more and more attention has been paid 
to the study of drug-drug interaction. Knowledge about the 
nature of such interactions and their quantification may help 
to avoid intoxication, especially in those cases where seve­
ral drugs are given concomitantly, while it may serve the 
improvement of pharmaco-therapy based on such an interaction. 
In a pharmacokinetic study on the 
influence of probenecid on the plasma kinetics and the renal 
handling of some organic anions, known to be transported by 
the tubular secretion mechanism in the mammalian kidney, we 
measured plasma levels and urinary excretion rates of sali­
cyluric acid in male Beagle dogs after intravenous appli­
cation with and without co-administration of probenecid. 
17.2 Materials and methods 
The materials and methods for the animal experiments are listed 
in section B, chapter 4. Probenecid was obtained from Sigma 
St. Louis (Mo. U.S.A.). Salicyluric acid and all other rea­
gents and solvents used were obtained from Merck, Darmstadt 
(G.F.R.) . 
Salicyluric acid was determined according to the HPLC-method 
as described in section B, chapter 7.1. 
The determination of probenecid was performed as described 
in section B, chapter 5. 
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Inulin was determined using the spectrophotometrical method 
described in section B, chapter 8.3. 
The extent to which salicyluric acid is bound to plasma 
proteins was measured by ultrafiltration through Visking 
dialysis tubing, as described in section B, chapter 6.4. 
Computer facilities and programming are shortly described 
in section B, chapter 8.6. 
17.3 Results 
Experiments 
In a series of experiments, each of three dogs was used two 
times. During the first experiment the animals received an 
intravenous dose of 1 gram salicyluric acid, given as a 5% 
aqueous solution containing an equimolar amount of sodium-
bicarbonate. 
In the second experiment the same dose of salicyluric acid 
was given after pre-administration of probenecid. In order 
to maintain a fairly constant plasma concentration of pro-
benecid, the dogs received a priming dose of 40 mg probene-
cid (1.6 ml of a 2.5% solution) followed by a constant in-
fusion of a solution containing 0.2% probenecid at a rate 
of 3ml/hr throughout the experiment. In this way a steady 
state probenecid concentration of 10-12 ymg/ml was obtained. 
As a representative example, figure 17.1 
shows the plasma concentration and the urinary excretion 
rate of salicyluric acid as a function of time after i.V. 
application of 1 gram salicyluric acid, with and without 
probenecid in one of the animals. 
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urinary excretion rate . 
( j ig/mm , tog scale) 
Ι Ο Ο Ο Ο Ί 
plasma cone 
( μ ς /ml, log scale) 
lOOChl 
1 gram salicyluric acid ι ν 
1 gram salicyluric acid LV 
with probenecid(12>ig/ml) 
3 0 0 -
Pig 17.1 Représentative example of the urinary excretion ratea 
and the plasma levels as a function of time after 
rapid i.V. administration of 1 gram salicyluric acid 
with and without concomitant administration of 
probenecid to dog 2. 
plasma kinetics 
After a relatively rapid distribution phase, the semi-
logarithmic plots of the plasma concentration versus time 
show a typical non-linear course, implying that at least 
one of the elimination routes of salicyluric acid becomes 
capacity limited at high plasma levels. The influence of 
probenecid mainly manifests itself in a significant enhanc-
ment of the terminal biological halflife, as can be cal-
culated from the slopes of the terminal phases in the plasma 
curves. 
Mathematically these kinds of non-linear plasma curves can 
be described using models as described by Van Ginneken et al. 
(10), 
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who derived general integrated equations, which describe the 
time course of the plasma concentration under the assumption of 
elimination by a saturable enzym system according to Michaelis 
Menten kinetics, in combination with normal first order 
elimination processes. As they argued, the rapid distribution 
phase can often be neglected since it is fast with respect to 
the terminal log-linear slope · By assuming furthermore that 
the drug is homogeneously distributed over a volume V,, they 
arrived at the following implicit equation for the plasma 
concentration C: 
In С = In A(0) + „fj. . In l+(l-f) A(0)/Km l+(l-f) C/Km -k.t (1) 
where: С - the plasma concentration 
A(0) = the apparent initial concentration extrapolated 
to zero time 
f = fraction of the total body clearance that occurs 
via the capacity limited elimination route 
Km = the apparent Michaelis-Menten constant for the 
capacity limited elimination route 
к « the rate constant of elimination at sufficiently 
low plasma concentrations (C-¿<Km) where 
linear kinetics apply 
The measured plasma curves were fitted according to equation 
(1), using the non-linear least square fit program Farmfit. 
Table 17.1 gives values of the most important parameters ob-
tained from these fits. 
From these results however no further information is obtain-
ed about the nature and the actual mechanism of the inter-
action. They merely show, that the interaction of probenecid 
on the kinetics of salicyluric acid causes a significant 
decrease in the total body clearance, while the fraction 
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of that clearance that occurs via the capacity limited 
elimination route is also significantly reduced. No effect 
was found on the distrxbution volume (V.) and the Michaelis-
Menten constant (Km). 
,ΤαοΙβ 17.1 Values of the parameters describing the plasma kinetics of 
salicyluric acid in the dog, after ί.υ. application of 
1 gram of the drug with and without concomitant application 
of probenecid. The values were estimated by fitting the 
experimental data according to equation 1, using a non­
linear least square fit program (Farmfit). 
dog 
no. 
1 
1 
2 
2 
3 
3 
experiment 
salicyluric acid 
control 
salicyluric acid 
with probenecid 
salicyluric acid 
control 
salicyluric acid 
with probenecid 
salicyluric acid 
control 
salicyluric acid 
V, 
(m!) 
3500 
2900 
4300 
4400 
3800 
3900 
f 
0.95 
0.14 
0.94 
0.47 
0.59 
0.22 
Km 
(^ лд/ті) 
335 
147 
143 
118 
20 
44 
k
 -1 (min 1) 
0.030 
0.019 
0.031 
0.021 
0.030 
0.014 
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Urinary excretion 
In the experiments without probenecid some 63+ 3% of the dose 
salicyluric acid was recovered unchanged from urine; this 
value decreases to 53%+ 2% in the experiments with probenecid. 
The rest of the dose is eliminated by other, presumably hepatic 
pathway(s). No salicylic acid could be detected in the urine/ 
indicating that the uncoupling reaction from salicyluric acid 
to salicylic acid as found in the rat (11) , does not take place 
at a significant rate in our experiments. 
One of the most illustrative ways to depict the relation between 
plasma levels of a drug and its urinary excretion rate is a 
linear plot of the excretion rate against the average plasma 
concentration over each urine collection period. Figure 17.2 
shows such plots for salicyluric acid with and without probe-
necid in one of the dogs. 
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urinary excretion rate (до/тіп) 
10 000 
1 gram salicyluric acid ι ν 
1 gram salicyluric acid i.v. with probenecid 
(10.4)ig/ml) 
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300 
plasma cene, (^g / ml Ϊ 
Fig 17.2 The relationship between the urinary excretion rate 
and the plasma concentration of salicyluric acid as 
measured after i.V. administration with and without 
probenecid to dog 1. It is obvious that the curves 
are the result of combined glomerular filtration and 
tubular secretion, probenecid inhibiting the active 
secretion of salicyluric acid. The lines connecting 
the experimental data points are simulations accor­
ding to the kidney model described in fig 17.3, using 
the parameters listed in table 17.2. 
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As can be seen from this figure, the renal excretion of 
salicyluric acid clearly exceeds the amount of drug that enters 
the urine by means of glomerular filtration, indicating tu-
bular secretion of the compound. At high plasma levels 
the secretion mechanism becomes saturated and the curves start 
to run parallel to the indicated glomerular filtration rate. 
This glomerular filtration rate can be calculated as the 
product of the measured inulin clearance and the free fraction 
of the drug, the fraction of drug bound to plasma proteins 
not being available for filtration. The inulin clearance and 
the fraction of free salicyluric acid remained unchanged 
throughout the course of an experiment. Probenecid causes a 
significant reduction in the amount of salicyluric acid which 
is actively secreted. 
For the kinetic analysis of the relation between urinary 
excretion rate and plasma concentration, we used the dynamic 
model, as described in section D, chapter 12. 
The model uses functional parameters for the description of 
the prevailing transport processes (e.g. glomerular filtra-
tion, tubular secretion, active and passive reabsorption). 
The reason for developing this model was, that the classical 
approach, where the renal excretion of a drug is described 
by simply summing up the contributions of the excretion 
mechanisms, in various cases fails to describe the experimen-
tal data adequately. 
Figure 17.3 shows a scheme of the model we used to simulate 
the tubular titration curves of salicyluric acid. 
A summary of the parameters obtained from the experiments 
and the simulations performed with the aid of the simulation 
program CSMP-III, is given in table 17.2. 
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QR-QU 
Fig 17.3 Model for the renal excretion of ealicyluria acid. 
1= central compartment; 2= renal plasma compartment; 
3= tubular compartment; Q
r
„
=
 glomerular filtration 
rate of the compound; Qr,= rate at which plasma per­
fuses the kidney tubules; Q..- urine flow; Tm= maxi­
mum transport capacity ; K„= Michaelis-Menten constant 
for the tubular secretion of the compound. 
In these simulations ι as a first approximation, the time 
dependent course of the plasma concentration of salicyluric 
acid was described by a bi-exponential function of the well 
known form: 
С = C(0). е" к1 Ъ + C(0). -k2t (2) 
where: С = plasma concentration 
C(0).= the intercept of the various phases at the 
concentration axis 
k. = the rate constants characterizing the slope 
1
 of the various phases. 
By adjusting the values of C(0). and k., adequate approxi­
mations of the individual plasma curves could be obtained, 
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necessary to account for possible effects of the renal delay 
time on the shape of the tubular titration curves measured 
when using the single injection technique (12). 
Figure 17.2 already shows experimental data and the curves 
simulated according to the model as an example. The effect 
of probenecid on the tubular secretion of salicyluric acid 
as indicated by the results in table 17.2 seems to be of a 
non-competitive nature, since only the values obtained for 
Tm in the experiments with probenecid are significantly 
decreased as compared to the control values, while the 
values of Km do not show remarkable changes. 
The parameters obtained from the simulations according to 
the model as outlined above, were used in a physiological 
based pharmacokinetic model we constructed for the simul-
taneous description of the plasma and urinary excretion 
kinetics of salicyluric acid, and the influence of probe-
necid. 
Figure 17.4 shows a schematic representation of the model, 
that consists of a two compartment model, to which the 
kidney model was allocated as to account for the renal 
clearance of the compound,while a linear clearance constant 
was introduced to represent the extra-renal clearance 
pathway. 
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Table 17.2 Values of the parameters characterizing the renal hand-
ling of salicyluric acid and the influence of probenecid 
Tm and K- are estimated by simulating the experimental 
data according to the model described in fig 17.3. For 
QR a value of 11 ml/min.kg tías taken (13); for Kg a value 
of 10 ml was taken (14); V3 being calculated (see section 
Ό equation 12). The other parameters listed were experi­
mentally measured. 
dog 
no. 
experiment free 
(%) 
mean plasma _L 0 
concentration inulin U Tm *R "" "τ 3 2 probenecid 
(yug/ml) (ml/min) (ml/min) (ml/mln) (^ g/min) (yUg/ml) (ml) (ml) 
1 salicyluric acid 36 
control 
1 salicyluric acid 39 
with probenecid 
2 salicyluric acid 42 
control 
2 salicyluric acid 40 
with probenecid 
3 salicyluric acid 57 
control 
3 salicyluric acid 52 
with probenecid 
10 + 1 
12+1 
12+1 
43+3 
44+4 
35+3 
36 + 3 
43+4 
40+4 
0.9+0.2 
0.9+0.2 
1.0+0.2 
0.9+0.2 
0.9+0.2 
1.1+0.2 
160 
165 
127 
143 
135 
138 
4000 
2200 
4900 
2000 
1600 
200 
15 
19 
20 
28 
17 
17 
1.4 
1.4 
1.5 
1.4 
1.4 
1.7 
10 
10 
10 
10 
10 
10 
CL«, 
4 . K -
—κΖΓ~* 
Γ" 
3 
J^ 
1 
(K T ,C 2 ) 
^ 
2 
OR-QU 
Fig 17.4 Model /or the eimultaneouB description of urinary 
excretion rate and plasma levels of salicyluric acid 
after rapid i.V. application to dogs. The model con­
sists of a two compartment model, to which the kidney 
model was allocated. CL = the extra renal clearance 
constant for the compound; k.. and k.. - rate constants 
for transport of drug, between the compartments 1 and 4. 
The other parameters are defined in fig 17.3. 
The following set of equations governs the transport rates 
of the drug in and out of the various compartments : 
dA 
^
1
 = lc41.A4 + (Q R-Q 0).C 2 - (CL e +Q R).C 1 - lcl4.A1 (3) 
dAj 
dt (QR-QGF> -S -
Tm 
(к
т
+с2) «R-ty .c. 
(4) 
dA3 
dt QGF-C1 + (K.J.+CJ) ·Ζ2 " QÜ' C3 (5) 
dt k14 - Al " ^ І ^ Д (6) 
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\ = Qü . C3 (7) 
ci = Ai/Vi (e) 
C2 = A2/V2 (9) 
C3 = A3/V3 (10) 
where CL » the extra-renal clearance constant (ml/min) 
k.. and 4., = the rate constants for transport of 
drug between compartment 1 and 4 (min ) 
V. = the volume of the central compartment 1 (ml) 
As a representative example figure 17.5 shows experimental 
data and the curves simulated according to the model as 
outlined above, in one of the animals. 
Table 17.3 shows values of the additional parameters ob-
tained from these simulations (CL , v., к,., Ьді)· 
As already mentionned above, the other parameters (Q_, K_, 
Tm, V,, V,) were obtained from the simulation of the 
urinary excretion data according to the kidney model (figure 
17.3), or directly from the experiments (Q__,Q_); also 
these parameters are listed in table 17.2. 
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Table 17.Ζ Values of the additional parameters obtained by simula­
ting the experimental plasma and urinary excretion curves 
according to the model described in fig 17.4. CL
e
= 
the extra renal clearance constant for salicyluric acid; 
kjg and kj2 - the "'ate constants for the transport of drug 
between the compartments 1 and 4; Kj^ the volume of the 
central compartment; the other parameters (QR, Kf, Tm, Vg« 
VS> QGF and Qui ar'e Usted in table 17.Ζ and were obtained 
from the simulation of the urinary excretion data according 
to the kidney model (fig 17.3), or directly from the 
experiments. 
dog 
1 
1 
2 
2 
3 
3 
experiment 
salicyluric acid 
control 
salicyluric acid 
with probenecid 
salicyluric acid 
control 
salicyluric acid 
with probenecid 
salicyluric acid 
control 
salicyluric acid 
with probenecid 
CL
e 
(ml/min) 
22 
25 
20 
17 
22 
24 
Vl 
(ml) 
1000 
1000 
1000 
Θ00 
1100 
1000 
k4l 
(min 
0.071 
0.067 
0.100 
0.091 
0.091 
0.083 
k
^-i (min 1) 
0.17 
0.17 
0.17 
0.17 
0.17 
0.17 
ui mai y 
(>ig/mi 
10000-
3000-
plasma 
(>4<ml, 
1000-
300-
100: 
30-
10-
3-
c 
ι , log scale) 
:onc 
юд scale) 
\ 
^ 
) 
с 
Э 
χ* 
V b , 
10O 
XX-1 
1 л г а т «alirtfJiir-»- a<4rt ι ι/ 
ч 
\ 
1 gram salicyluric acid ι ν 
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Fig 17.5 A representative example of the experimentally ob­
tained plasma and urinary excretion rate curves and 
the curves simulated according to the model in fig 
17.4 in dog 1, using the parameters listed in 
tables 17.2 and 17.г 
17.4 Discussion 
In the present paper a model for the simultaneous description 
of the plasma kinetics and the urinary excretion of salicy­
luric acid is outlined. With the aid of this model it appears 
to be possible to quantify the interaction between probenecid 
and this drug. The change in plasma levels and in urinary 
excretion rates under the influence of probenecid can be 
adequately accounted for in terms of a non-competitive inhi­
bition of the tubular secretion of salicyluric acid. 
No effect was measured on the binding of salicyluric acid to 
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plasma proteins nor on its distribution characteristics 
(tables 17.2 and 17.3). The extra-renal elimination pathway 
of salicyluric acid was also not affected by probenecid. 
No further information about the nature of this elimination 
route was obtained from our experiments. 
A possible deglycination reaction of salicyluric acid to 
salicylic acid as has been reported to occur in the rat (11), 
could not be detected,as the voided urine did not contain 
significant amounts of salicylic acid. 
One of the plasma curves,however, showed an unexpected rise 
after 260 min, while the urine excretion rose parallel to it, 
perhaps indicating some enterohepatic circulation of the 
salicyluric acid but none of the other experiments conftrmed 
this phenomenon. 
From in vitro experiments (15,16) designed to study the influence 
of probenecid on the transport of organic anions in several 
kidney preparations (e.g. isolated tubules, kidney slices, 
membrane vesicles) no definite answer is obtained about the 
characteristics of this interaction. Probenecid is reported 
to behave as a competitive as well as a non-competitive 
inhibitor. In our experiments probenecid seems to behave in a 
non-competitive way. A possible explanation for the varying 
experimental findings can be found in differences of experi-
mental set-up in the various studies. 
The active transport must be looked upon as the sum of several' 
separate steps of transport (e.g from blood to interstitial 
tissue, from interstitial tissue to tubule cell, from tubule 
cell to tubular lumen) some of these steps being sensitive 
to probenecid. When one or more of these steps are studied 
separately, this can lead to different conclusions about 
the characteristics of probenecid action. 
In our approach we merely try to describe the transport 
process in a functional manner, while no information is 
obtained about the individual steps of transport. 
153 
Under the experimental conditions, we found that passive reab-
sorption of salicyluric acid as reported by Knoefel (17) plays 
no role of importance. Though the urinary pH in our experiments 
was not extremely high as compared to his experimental values, 
the urine flows in our experiments were 5-10 times as high. 
Under high flow conditions the renal delay time will be some 
1.5 minutes, while at flows of 0.2 ml/min this time increases 
rapidly (18), thereby allowing more reabsorption to take place. 
The kidney model we described here is able to account for these 
effects as well. 
The pH and urine flow influence on the kinetics of renal 
handling of salicyluric acid are currently under investigation. 
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CHAPTER 18 SIMULTANEOUS KINETIC MODELLING OF PLASMA LEVELS 
AND URINARY EXCRETION OF PHENOLSULFONPHTALEIN, 
AND THE INFLUENCE OF PROBENECID 
18.1 Introduction 
As stated in the previous chapter, in the last few years 
more and more attention has been paid to the study of drug 
interactions, also with respect to the renal clearance of 
drugs. Quantification of such interactions may help to avoid 
under-, or overdosing when several drugs interfering with 
eachothers elimination are given concomitantly. 
On the basis of these and other considerations and feeling 
the need for a general kinetic approach , we performed studies 
on the renal handling of drugs, known to be transported by 
the tubular secretion mechanism in the mammalian kidney, and 
possible drug interactions at that level. 
In this report a study is presented on the influence of 
probenecid on the kinetics of plasma levels and urinary 
excretion rates of phenolsulfonphtaleln in the male Beagle 
dog. The interaction is described in a quantitative way. 
Phenolsulfonphtaleln (Phenol red) 
was one of the first compounds known to be secreted by the 
renal tubules (19) and its interaction with other compounds 
such as phenylbutazone (20), probenecid (21,22), para-
amino hippuric acid (23) and iodopyracet (24) has been well 
documented in various species. The studies in the literature 
however are mainly performed in vitro, while the few in vivo 
studies give little or no quantitative information. 
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18.2 Materials and methods 
The materials and methods for the animal experiments are 
listed in section B, chapter 4. Probenecid was obtained from 
Sigma St. Louis (Mo. U.S.A.). Phenolsulfonphtaleïn and all 
other reagents and solvents used were obtained from Merck 
Darmstadt (G.F.R.). 
Phenolsulfonphtaleïn was determined according to the spectro-
photometrical method described in section B, chapter 8.1, 
while the determination of probenecid was performed according 
to the HPLC-method as outlined in section B, chapter 5. 
Inulin was determined using the method described in section B, 
chapter 8.3. The extent to which phenolsulfonphtaleïn is bound 
to plasma proteins was measured by ultrafiltration through. 
Visking dialysis tubing, as described in section B, chapter 8.4. 
Computer facilities and programming are shortly described in 
section B, chapter 8.6· 
The experimental design was such that the dogs were used two 
to four times for an experiment. In the control experiments, 
the dog received an intravenous dose of 0.4 gram and/or 1.0 
gram phenolsulfonphtaleïn, given as a 7% aquaous solution 
containing an equimolar amount of sodium bicarbonate. 
In the experiments with probenecid, the same dose(s) of 
phenolsulfonphtaleïn were given after pre-administration of 
probenecid. In order to maintain a fairly constant plasma 
level of probenecid, the dogs received a priming dose of 
40-175 mg probenecid (1.6-7 ml of a 2.5% solution) immediately 
followed by a constant infusion of a solution containing 0.5% 
probenecid at a rate of 3-7 ml/hr. This way steady state 
probenecid concentrations of 10-124 ug/ml were obtained. 
Phenolsulfonphtaleïn was injected 30 minutes after the pri-
ming dose of probenecid. 
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18.3 Results and discussion 
Figure 18.1 shows plasma concentrations and urinary excretion 
rates as a function of time after i.v. application of 1 gram 
phenolsulfonphtaleïn, with and without probenecid in one of 
the animals. 
urinary excretion ra te -
( μ ς / ι η ι η , log scale) 
ЮОООт 
DOG2 
1 gram phenolsulfonphtaleïn ι ν 
1 gram phenolsulfonphtaleïn ι ν 
wi th probenecid 
3 0 0 0 -
plasma concentration 
(jj.g/ml,log scale) 
1000 
300 
100-
time(min) 
Fig 18.1 Representative example of the urinary excretion rates 
and plasma levels as a function of time after rapid 
i.V. administration of 1 gram phenolsulfonphtalein 
with and without concomitant administration of 
probenecid to dog 2. 
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The obtained plasma curves showed two distinct phases and 
can be mathematically described by the wellknown bi-exponen-
tial function (see also chapter 12). 
In table 18.1 the various relevant parameters obtained after 
i.v. administration of phenolsulfonphtaleln with and without 
probenecid are listed. The parameters were estimated on basis 
of non-linear regression analysis of the experimental data 
(Farmfit). 
From these results alone no further information is obtained 
about the nature and the actual mechanism of the interaction 
between probenecid and phenolsulfonphtaleln. They merely show 
that this interaction causes a significant decrease in the 
total body clearance in most of the experiments with probenecid. 
(see table 18.1 experiments D,F,H,L), while this effect seems 
to be lacking in the experiments В and J. 
The calculated volume of distribution increased in all cases 
under the influence of probenecid as compared to the control 
values, while the mean residence time also increased in all 
cases. 
The influence of probenecid on the distribution volume of 
phenolsulfonphtaleln was rather unexpected, since we found 
that probenecid does not interfere with the protein binding 
of phenolsulfonphtaleln. This effect therefore probably is 
not gained by an increased diffusion of the compound into 
the tissues, and must be due to non-linearities in the 
kinetics of phenolsulfonphtaleln at high plasma levels where 
the tubular secretion mechanism becomes saturated. 
Under the influence of probenecid the elimination rate at 
high plasma levels still decreases, and when the plasma curves 
are fitted (falsely) using the same linear open compartment 
model, the non-linearity causes changes in the distribution 
phase , that may lead to remarkeble changes in the rate 
constants describing the exchange of drug, between the central 
and the periferal compartment, which results in an increased 
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apparent volume of the central compartment (table 18.1). 
Due to these changes in volume of distribution the effect of 
probenecid on the clearance of phenolsulfonphtaleln is masked, 
as in the experiments В and J, where the effect of increasing 
volume of distribution completely compensates the decrease in 
clearance. 
The mean residence time, being much more sensitive to changes 
in the terminal phase of the interaction. The non-linear model 
which will be described below, accounts for all changes in a 
comprehensive and consistent way. 
In the experiments without probenecid 69+9% of the dose of 
phenolsulfonphtaleln was recovered unchanged from urine; 
Due to saturation of the renal clearance at high plasma levels, 
this percentage was consistently lower in the experiments 
with a dose of 1 gram (61+3%), as compared to the experiments 
with a dose of 0.4 gram (77+6%). 
In all experiments with probenecid, the percentage of the 
dose which was recovered unchanged from urine was also sig­
nificantly lower than in the corresponding control experiments, 
due to the inhibitory effect of probenecid on the tubular 
secretion mechanism of phenolsulfonphtaleln. The rest of 
the dose administered is eliminated by other pathways. 
In the dog bilairy excretion of the dye is reported (25), 
while during our experiments some salivary excretion was 
observed also. Figure 18.2 shows linear plots of the ex­
cretion rate against the average plasma concentration over 
each urine collection period for the compound, with and 
without probenecid in one of the dogs. For phenolsulfon­
phtaleln alone, similar plots have been reported by Shannon 
(26). The renal excretion rate of the dye clearly exceeds 
the amount being excreted through glomerular filtration, 
indicating tubular secretion. The glomerular filtration 
rate of the compound can be calculated as the product of 
the measured inuline 
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note: 
The control experiments are marked: (-), and the experiments with probenecid are marked (+). 
Table 18.1 Values of the parameters desaribing the plasma kinetics of 
phenolsulfonphtalein after i.v. application to dogs, with 
and without concomitant application of probenecid. The 
values were estimated by fitting the experimental data 
according to a linear open two compartment model. 
exp. dog dose exp. CfOJj C(0)2 kj k2 AUC CL MRT V, к , к V 
n o
·
 n o
· (/Ag/ml) (ywg/ml) (min-1) (min-1) (ywg.min/ml) (ml/min) (min) (1) (min"!) (min-1) (1) 
A 
В 
С 
D 
E 
F 
G 
H 
I 
J 
К 
L 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
4 
4 
0.4 
0.4 
0.4 
1.0 
1.0 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
143 
114 
275 
332 
78.1 
83.3 
232 
231 
147 
90.3 
263 
247 
42.0 
46.0 
122 
184 
26.9 
32.3 
171 
164 
49.2 
60.1 
166 
176 
0.051 
0.061 
0.050 
0.115 
0.048 
0.058 
0.105 
0.185 
0.062 
0.059 
0.077 
0.086 
0.014 
0.013 
0.017 
0.011 
0.015 
0.012 
0.015 
0.012 
0.016 
0.015 
0.017 
O.013 
5787 
5278 
12620 
19920 
3387 
4166 
13530 
14470 
5467 
5492 
1335Θ 
16200 
69 
76 
78 
50 
117 
96 
74 
69 
73 
73 
71 
62 
45 
54 
43 
81 
44 
62 
57 
74 
43 
52 
48 
64 
2.2 
2.5 
2.5 
1.9 
3.8 
3.5 
2.5 
2.5 
2.0 
2.7 
2.3 
2.4 
0.0102 
0.0171 
0.0086 
0.0520 
0.0087 
0.0178 • 
0.0374 
0.0867 
0.0147 
0.0142 
0.0215 
0.0296 
0.0225 
0.0270 
0.0268 
0.0480 
0.0236 
0.0249 
0.0534 
0.0844 
0.0275 
0.0327 
0.0400 
0.0435 
3.1 
4.1 
3.3 
4.0 
5.2 
5.9 
4.2 
5.1 
3.1 
3.8 
3.6 
4.0 
urinary excretion r a t e 
(ug/mm) D O 6 1 
QQQQ 1 gram phenolsulfonphtalem i v. 
1 gram phenolsulfonphtalem i.v 
wi th probenecid 
6 0 0 0 
4 0 0 0 
2 0 0 0 
200 
plasma cone ( j ig/ml) 
Fig 18.2 The relationship between the urinary excretion rate 
and the plasma concentration of phenolsulfonphtalein 
as measured after i.V. administration with and with­
out probenecid to dog 1. It is obvious that the curvee 
are the result of combined glomerular filtration and 
tubular secretion, probenecid inhibiting the active 
secretion of phenolsulfonphtalein. The lines connec­
ting the experimental data points, are simulations 
according to the kidney model described in fig 18.Ζ 
using the parameters listed in table 18.2. 
clearance and the free fraction of drug, the fraction of drug 
being bound to plasma proteins not being available for fil­
tration. The inulin clearance and the free fraction of phenol­
sulfonphtalein remained essentially unchanged throughout an 
experiment. Probenecid causes a significant decrease in the 
amount of dye which is actively secreted. 
For the kinetic analysis of the relation between urinary 
excretion rate and the plasma concentration, we used the 
general dynamic model, which accounts for the various aspects 
of renal functionning, and which was described in detail in 
section D, chapter 12. 
Figure 18.3 shows a scheme of the model we used to simulate 
the tubular titration curves of phenolsulfonphtalein. 
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I 
Qn 
Tm 
^|ус
г
) 
OP 1 QR-QU 
Fig 18.3 Model for the venal excretion of phenoleulfonphtalein. 
1= central compartment, 2= renal plasma compartment; 
3= tubular compartment ; Q
r
p- glomerular filtration 
rate of the compound; Q„= rate at which plasma perfu­
ses the kidney tubules ; Q.,- urine flow; Tm= maximum 
transport capacity ; К = Michaelis-Menten constant for 
the tubular secretion of the compound. 
Like in chapter 17, for Q,, a value of 11 ml/min.kg was taken and 
к 
for the volume of the renal plasma compartment a value of 10 
т1.фЬе volume of the tubular compartment was calculated as 
the product from the urine flow and the renal delay time 
(1.5 minutes in this case). 
With the aid of the simulation program CSMP-III, the experi­
mental urinary excretion rate versus plasma concentration curves 
were simulated according to this model. A summary of the 
parameters obtained from these experiments and the simulations 
is given in tab!«· 18.2. 
In these simulations, as a first approximation, the time dep­
endent course of the plasma concentraion of phenolsulfonphta-
leln was described by the bi-exponential function. Using the 
values of С(0). and k. obtained from the fits of the indivi­
dual plasma curves, adequate approximations of the experimen­
tal curves could be obtained. 
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Figure 18.2 already shows as an example, experimental data 
and the curves simulated according to the model. 
The effect of probenecid on the tubular secretion of phenol-
sulfonphtaleln as indicated by the results in table 18.2, 
seems to be a competitive inhibition, since the changes in 
the curves can be adequately accounted for in terms of in­
creases in the KT values, without changes in the values for 
Tm. In the experiments with low doses of the dye (0.4 gram) 
the obtained tubular titration curves show little saturation 
and in those cases only the ratio Tm/K could be determined 
from the slope of the curves at low plasma levels and not 
Tm and К separately. 
The parameters obtained from the simulations, were used in 
a physiologically based pharmacokinetic model we constructed 
for the simultaneous description of the plasma and urinary 
excretion kinetics of phenolsulfonphtaleln, and the influence 
of probenecid. The model (see figure 18.4) was discussed in 
detail in chapter 17 t 
c u 
Κι 1 
α, iL "SfroR-Qer 
7 
(K T .C 2 ) 
< V Q U 
Fig 18.4 Model for the simultaneous description of итіпагу 
excretion rate and plasma levels of phenoleulfon-
phtalein after rapid i.V. application to dogs. 
The model consists of a two compartment model to 
which the kidney model (fig 18.3) was allocated. 
CL = the extra renal clearance constant for the 
compound; îc and к .^= the rate constants for trans­
port of drug between the compertments 1 and 4. The 
other symbols are defined in fig 18.3. 
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note: 
The control experiments are marked: (-), and the experiments with probenecid are marked (+). 
Table 18.2 Values of the parameters oharacterizing the renal handling 
of phenolsulfonphtalein and the influence of probenecid. 
Tm and Kf are estimated by simulating the experimental 
data according to the model described in fig 18.3. For 
QR a value of 11 ml/min.kg (IS) was taken; for fg a value 
of 10 ml (14) was taken;V¡ being calculated using equa-
tion 12 of section D. The other parameters listed were 
experimentally measured. 
exp. 
no. 
A 
В 
С 
D 
Б 
F 
G 
H 
I 
J 
К 
L 
dog 
no. 
dose 
(g) 
0.4 
0.4 
1.0 
1.0 
0.4 
0.4 
1.0 
1.0 
0.4 
0.4 
1.0 
1.0 
exp 
_ 
+ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
. conc. 
prob. 
(yug/ml) 
_ 
13 + 1 
-
124+6 
-
10+1 
-
45+2 
-
13+1 
-
58+2 
urine 
flow 
(ml/min) 
0.8+0.2' 
0.7+0.2 
0.9+0.2 
0.9+0.2 
1.0+0,1 
0.7+0.2 
0.8+0.2 
1.0+0.2 
0.5+0.2 
0.7+0.2 
1.1+0.2 
1.7+0.3 
CL 
inulin 
(ml/min) 
39+3 
42+4 
33+3 
35+4 
53+5 
46+5 
32+4 
33+3 
33+3 
45*4 
41+4 
43+4 
Tm 
(^ лд/тіп) 
_ 
-
7900 
7900 
-
-
8600 
8600 
-
-
10400 
10400 
K T 
(/лд/ті) 
_ 
-
66 
400 
-
-
66 
250 
-
-
80 
260 
Tm/KT 
95 
55 
120 
20 
170 
95 
130 
34 
80 
38 
130 
40 
free 
fraction 
0.20 
0.19 
0.23 
0.34 
0.25 
0.20 
0.25 
0.28 
0.16 
0.20 
0.25 
0.22 
V 2 
(ml) 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
V3 
(ml) 
1.2 
1.1 
1.4 
1.4 
1.5 
1.1 
1.2 
1.5 
0.8 
1.1 
1.7 
2.6 
QR 
(ml/min) 
138 
143 
143 
138 
182 
172 
169 
173 
145 
145 
151 
151 
As a representative example figure 18.5 shows experimental 
data and the curves simulated according to the model as outlined 
in chapter 17, in one of the animals. 
plasma concentration-
(¿ig/ml.log scale) 
1000-
-unnary excration rate 
Oig/min.log scale) 
10000 
3 0 0 -
1CX> 
3000 
:1000 
300 
100 
-30 
І-Ю 
time (mm) 
Fig 18.S A representative example of the experimentally ob­
tained plasma and urinary excretion rate curves and 
the curves simulated according to the model in fig 
18.4 in dog 1, using the parameters listed in tables 
18.2 and 18. 3. 
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Table 18.3 shows values of the additional parameters obtained 
from these simulations (CL , V , *,., and k.,). As already 
mentionned above, the other parameters (QR, К , V,, and V,) 
were obtained from the simulations of the urinary excretion 
data according to the kidney model (figure 18.3), or directly 
from the experiments (Q „and Q..) ; also these parameters are 
listed in table 18.2. 
In conclusion it appears that the changes in plasma levels 
and urinary excretion rates under the influence of probenecid 
can be adequately accounted for in terms of a competitive 
inhibition of the tubular secretion of phenolsulfonphtaleïn. 
From the obtained values of Tm and Κ , functional inhibition 
constants KT for probenecid can be calculated using the 
following formula: 
(Tra/KT)probenecid= ^ W control' j l + C ^ ) ( 1 1 ) 
experiment experiment 
in which : C- = plasma concentration of probenecid 
K- = inhibition constant for probenecid 
The values obtained for Kj are listed in table 18.3. 
No effect was measured on the binding of phenolsulfonphtaleïn 
to plasma proteins nor on its distribution characteristics 
(see table 18.2 and 18.3). The extra-renal elimination path-
way (s) of the dye was also not affected by the concomitant 
application of probenecid. Passive reabsorption of phenol-
sulfonphtaleïn as reported by some investigators (27) seems 
to play no role of significance under the applied experimen-
tal conditions, presumably due to the relative high urine 
flows. 
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Table 18.3 Values of the additional parameters obtained by simulating 
the experimental plasma and urinary excretion rate curves 
according to the model described in fig 18.4. CLe= 
the extra renal clearance constant for phenolsulfonphtalein 
kjj and k42- the rate constants for transport of drug 
between the compartments 1 and 4. Vj- the volume of the 
central compartment. The other parameters (QR, Kf, Tm, Fj, 
V¡, QQF and Qy) are listed in table 18.S and were obtained 
by simulating the urinary excretion data according to the 
kidney model (fig 18.Si, or directly from the experiments. 
exp. dog kl4 k41 V1 CLe 14 
no. (min-1) (min-1) (1) (ml/min) (мд/ml) 
A l 14 
B I 30 
1 0.033 0.037 1.9 3 3 
D 1 26 
E 2 22 
F 2 35 
2 0.036 0.045 2.5 2(¡ 
H 2 39 
1 3 22 
j
 3 0.035 0.042 2.3 29 12 
К 4 30 
. 0.050 0.056 2.3 ,, 26 
L 4 33 
18 
25 
13 
16 
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section F 
C O N C L U D I N G R E M A R K S 
In this thesis about the mathematical description of the 
relation between plasma concentration of a drug and its 
urinary excretion rate, two principally different pharmaco-
kinetic models are discussed. 
The model which, in this context is referred to as the 
classical model, and which is described in detail in section 
C, can be regarded as an example of the traditional pharma-
cokinetic models. In most of these models, the clearance 
function operates directly from the central compartment. 
In that case the elimination rate of the drug is directly 
proportional to the drug concentration in that compartment. 
The alternative model, we developed 
and which is described in section D, on the other hand may 
be called representative for a new line of models in 
pharmacokinetics, the so called physiologically based 
pharmacokinetic models. These models use known anatomical 
and physiological functions as a basis for the mathematical 
description of drug concentrations throughout the body. 
In this type of model the elimination of drug occurs from 
compartments representing the various clearing organs, and 
which are perfused with blood from the central compartment. 
In this case the elimination rate of a drug from the body 
is not necessarily directly proportional to the drug 
concentration in the central compartment. In contradiction 
to the classical models these models can be used to describe 
supply-, and capacity limited processes simultaneously, and 
the transition from one form to the other occurs in a 
continuous way. 
As can be seen in chapter 12 and 14, the new kidney model 
in extension to the classical model, can describe the tubular 
titration curves of iodopyracet and salicylic acid better 
than the classical model, for in those cases the kinetics of 
urinary excretion become supply limited at low plasma levels 
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of both compounds, while at high plasma levels the excretion 
mechanism becomes capacity limited. 
Also the influence of urine flow and urinary pH on for instance 
the renal excretion of weak acids and bases can be accounted 
for in a rational manner, using the kidney model (see chapter 15) 
The classical approach is considerably less adequate to do so 
(see chapter 10). 
In combining the various models described in section D, for 
the description of tubular secretion,glomerular filtration, 
passive and active reabsorption, a general kidney model can 
be conceived. As an example the figure shows such a general 
kidney model. 
\ . 
proximal 
tubular 
compartment 
> 
distal 
tubular 
compartment 
</GF 
4 T S 
AR
 fc 
central 
compartment 
If 
tubular 
cell 
compartment 
PR 
F - 0 G F 
L-IS_J 
AR 
i 
renal plasma 
compartment 
F-lu 
renal plasma 
compartment 
F-(u 
Schematic representation of a general kidney model for the 
description of the relation between plasma concentrations 
and urinary excretion rates of a drug. VQF= glomerular fil-
tration rate; F= renal plasma flow; fu= urine flow; TS= 
tubular secretion; AR= active reabsorption and PR= passive 
reabsorption. 
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The tubular and the renal compartment are subdivided into 
a number of smaller sections (in this case two ). This 
division into smaller segments makes it possible to locate 
the various transport mechanisms to that part of the kidney 
from where they take place in vivo. It allows also the 
generation of a pH gradient along the tubule, simulating 
the actual pH in the various parts of the tubule, which may 
be of importance for the description of the passive reabsorp-
tion processes. 
Some drugs are accumulated in the renal tissues before being 
excreted into the urine. For these situations a renal tissue 
compartment is incorporated into the model as well. 
The clinical importance of the investigated substances, used 
to test the validity of the proposed model is not very large 
but in future experiments the model can be used to provide for 
a rational basis of dosis adjustment in cases of impaired 
renal functionning, or when two or more drugs given concomitantly 
influence eachothers renal clearance. The model may also be 
useful in studies aimed to characterize the various renal 
transport mechanisms. Especially for the active transport 
mechanisms (tubular secretion and active reabsorption) the 
precise nature and structure of the so called carriers are 
not yet revealed. While most investigations, in which attempts 
are made to find the structural requirements for a drug to fit 
the carrier molecule are based predominantly upon observations 
about whether drugs with given structures are secreted or not, 
the model we described is able to characterize the transport 
mechanisms by means of values for the maximum transport capa-
city and the affinity constant for the drug towards the carrier. 
The latter allows a more detailed investigation of the influence 
of substituents on the excretion pattern then was possible 
before. 
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SAMENVATTING 
Dit proefschrift is gewijd aan het .modelmatig beschrijven van 
de renale excretiepatronen van farmaca in relatie met hun 
plasmaconcentratie, en de toepassing ervan in interactiestudies. 
Het kwantificeren van deze voorname eliminatieroute, waarlangs 
geneesmiddelen en hun metabolieten uit het lichaam kunnen wor-
den verwijderd, alsmede van mogelijke geneesmiddel-interacties 
op dit niveau, zou in belangrijke mate kunnen bijdragen tot 
het vaststellen van correcte doseringsschema's in de farmaco-
therapie, speciaal in patiënten met een gereduceerde nierfunctie. 
In die zin zou het helpen relatieve overdosering en daaruit 
voortkomende toxische reacties tijdens chronische therapie te 
voorkomen. Alhoewel er veel onderzoek is gedaan naar de kwali-
tatieve aspecten van de renale klaring van geneesmiddelen, is 
er in de literatuur relatief weinig aandacht aan de kwantitatieve 
aspecten besteed. 
Het proefschrift is onderverdeeld: in zes secties. 
Sectie A omvat een beknopte inleiding in de farmacokinetiek, 
de nieranatomie en de nierfysiologie. 
In sectie В wordt een beschrijving gegeven van de gebruikte 
materialen en methoden. In de experimenten werd gebruik gemaakt 
van mannelijke Beagle-honden. Nadat de honden onder narcose 
waren gebracht, werden voorzieningen aangebracht voor het nemen 
van bloed-, en urinemonsters. Voor het kwantitatief opvangen van 
urine werd een cathetersysteem ontworpen met de mogelijkheid 
om de blaas aan het einde van een opvangperiode te spoelen met 
fysiologisch zout. Na intraveneuze toediening van de te onder­
zoeken stof(fen), werden op gezette tijden bloed-, en urine­
monsters genomen. Voor de bepaling van deze, over het algemeen 
zeer polaire, stoffen in plasma en urine, werd hoofdzakelijk 
gebruik gemaakt van hoge druk vloeistofchromatografie. 
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In deze sectie wordt een aantal van deze methoden beschreven, 
o.a. voor iodopyracet, probenecide, salicyluurzuur en paracetamol-
glucuronide. Een van de grootste voordelen van deze analyse­
methodiek is wel de .eenvoudige opwerking van de monsters, die 
vaak neerkomt op een eenvoudig verdunnen (dit in tegenstelling 
tot diverse gaschromatografische technieken, die derivatisering 
veelal noodzakelijk maken). Ook de overige technieken zoals de 
bepaling van inuline, het meten van de eiwitbinding van de 
gebruikte stoffen en de isolatie van het gebruikte paracetamol-
glucuronide worden in deze sectie uitvoerig beschreven. In het 
laatste deel van de sectie worden ook de gebruikte computer­
faciliteiten en programmering in het kort genoemd. Voor het 
fitten van de plasma curves werd gebruik gemaakt van Farmfit, 
een computerprogramma voor niet-lineaire regressie.-analyse, 
terwijl voor de simulaties het CSMP-III pakket werd gebruikt. 
In de secties С en D worden twee principieel 
verschillende famacokinetische modellen besproken voor de 
mathematische beschrijving van de renale excretiepatronen. 
Het model, dat in deze context het klassieke model wordt 
genoemd, kan worden beschouwd als een voorbeeld van de tradi­
tionele farmacokinetische modellen. In de meeste van deze mo­
dellen werkt de klaringsfunctie rechtstreeks vanuit het centrale 
compartiment. Evenals in het model, dat gedetailleerd wordt 
beschreven in sectie C, is de eliminatiesnelheid van de stof 
in dat geval recht evenredig met de concentratie in dat centrale 
compartiment. 
Het alternatieve model, dat we ontwikkelden, en dat in detail 
wordt beschreven in sectie D, kan worden beschouwd als zijnde 
representatief voor een nieuw type farmacokinetische modellen, 
de zogenaamde fysiologische farmacokinetische modellen. 
In deze modellen wordt gebruik gemaakt van bekende anatomische 
en fysiologische functies voor de beschrijving van farmacon-
concentraties in de diverse delen van het lichaam. In deze 
modellen opereert de klaringsfunctie vanuit compartimenten, 
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die de klarende organen voorstellen (bijv. leverfnier). 
In dit geval is de eliminatiesnelheid van het farmacon niet 
noodzakelijkerwijs recht evenredig met de concentratie in 
het centrale compartiment. In tegenstelling tot de klassieke 
modellen, zijn deze modellen in staat flow-, en capaciteits-
beperkte eliminatieprocessen gelijktijdig te beschrijven. 
Zoals uit de resultaten van de hoofd-
stukken 12 en 14 blijkt, is het nieuwe, door ons ontwikkelde 
niermodel beter in staat de tabulaire titratiecurves van 
iodopyracet en salicylzuur te beschrijven, dan het klassieke 
renale klaringsmodel. Met name voor deze beide stoffen geldt, 
dat bij lage plasmaconcentraties de renale uitscheidings-
snelheid flowbeperkt wordt, terwijl bij hoge plasmaspiegels 
de elirtiinatie capaciteitsbeperkt wordt. 
Gebruik makend van dit model, kunnen ook de invloeden van 
urineflow en urine-pH op de renale klaring van bijvoorbeeld 
een zwak zuur op inzichtelijke wijze worden beschreven, 
hetgeen met behulp van het klassieke model nauwelijks of in 
het geheel niet mogelijk is (zie ook hoofdstuk 15). 
In tegenstelling tot het klassieke model, houdt het nieuwe 
model <S6k rekening met de zogenaamde "renal delay time", 
die met nane in het geval van snelle intraveneuze injecties 
een vervorming van de tabulaire titratiecurves teweegbrengt 
(zie hoofdstuk 13). 
Sectie E behandelt de toepassing van het ontwikkelde nier-
model in een tweetal interactiestudies met probenecide. 
Probenecide is een stof, die de actieve transportmechanismen 
voor diverse organische anionen remt, en als zodanig wordt 
deze stof bijvoorbeeld wel toegepast bij de farmacotherapie 
van een aantal infectieziekten. Probenecide verlengt de 
biologische halfwaardetijd van de gebruikte antibiotica door 
remming van hun tabulaire secretie. 
In onze studies werd de invloed van probenecide op de kinetiek 
van plasmaconcentraties en renale excretie gemeten voor: 
177 
fenolsulfonftaleine en salicyluurzuur (hoofdstukken 17 en 18). 
Zoals uit de resultaten blijkt, remt probenecide de secretie 
van salicyluurzuur op een non-competitieve wijze, terwijl het 
daarentegen de secretie van fenolsulfonftaleme op competitieve 
wijze remt. Met behulp van het niermodel konden functionele 
parameters worden gemeten, die een zekere voorspellende waarde 
hebben voor het onderkennen van deze interactie. 
Het klinisch belang van de onderzochte stoffen, die gebruikt 
werden om het door ons ontwikkelde model te testen, is weliswaar 
niet erg groot, maar het model kan zorgen voor een rationele 
basis bij het aanpassen van doseringsschema's in het geval van 
verminderde renale functie, of in het geval dat twee of meer 
geneesmiddelen, die tegelijk worden gegeven eikaars renale 
klaring beïnvloeden. Het model kan ook met succes toegepast 
worden in studies, die er naar streven de verschillende renale 
klaringsmechanismen te karakteriseren. Speciaal in het geval 
van de actieve transportmechanismen geldt, dat de ware aard 
en structuur van de zogenaamde carrier-moleculen nog niet 
bekend is. Terwijl de meeste studies, waarin pogingen worden 
gedaan om de structurele eisen te vinden waaraan een farma-
con moet voldoen om op de carrier te passen, gebaseerd zijn 
op waarnemingen of een farmacon met een gegeven structuur al 
dan niet wordt gesecerneerd, is het nieuwe model in staat 
het transportmechanisme te karakteriseren met behulp van 
operationele parameters. Dit laatste laat een gedetailleerder 
onderzoek toe naar de invloeden van bepaalde substituenten 
op het excretiepatroon. 
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STELLINGEN 
I 
Experimenten, waarin de actieve reabsorptie van para-amino-
hippuurzuur wordt aangetoond, wijzen erop, dat bidirectioneel 
actief transport van stoffen door de nier een algemener feno­
meen is, dan tot noch toe wordt aangenomen. 
W.B. Kinter, Am. J. Physiol., 19±, 1141 (1959). 
II 
Actieve reabsorptie vertoont evenals passieve reabsorotie 
een urineflow afhankelijk gedrag. 
Dit proefschrift. 
III 
De niet-lineariteit in de tabulaire titratiecurves van 
Pindolol zijn mogelijk ббк te verklaren door veranderingen 
in de eiwitbinding van deze stof bij hogere plasmaconcentraties. 
L. Balant et. al., Eur. J. Clin. Pharmacol., 21, 65 (1981). 
IV 
In tegenstelling tot wat in de praktijk wordt beweerd, verlengt 
Tomanol de wachtperiode voor het slachten van met penicilline 
behandelde koeien.(Boerenbedrog??). 
P. Hekman et. al.. Vet. Quart., 4, 12 (1982). 
V 
Bij de beschrijving van de farmacokinetiek van benzoëzuur in de 
mens, dient gebruik te worden gemaakt van modellen, die in staat 
zijn de abrupte overgang van een capaciteitsbeperkte naar een 
flow-beperkte eliminatie voor deze stof te beschrijven. 
VI 
De in de literatuur beschreven invloed van probenecide OD het 
schijnbare verdelingsvolume van ampicilline, is het gevolg 
van een minder juiste kinetische analyse. 
M. Gibaldi, Clin. Pharm., О, 346 (1968). 
VII 
Voor een betere integratie van de lichamelijk gehandicapte in 
ons maatschappelijk verkeer, is het zinvol niet alleen het ac­
cent te leggen op een verandering van de attitudes en gedragingen 
van de lichamelijk valide mensen t.o.v. hun lichamelijk gehandi­
capte medemensen, maar tevens de attitudes en gedragingen van 
lichamelijk gehandicapte medemensen in ogenschouw te nemen, en 
waar nodig te veranderen. 
P.M. Sanders, doctoraalscriptie. 
VIII 
Dat dansen in Nederland nog steeds niet als sport wordt erkend, 
moet grotendeels worden toegeschreven aan krachten binnen de 
dansbond(en) zelfiï. 
IX 
Elk model is minder dan de werkelijkheid, behalve een foto-
model , dát is méér dan de werkelijkheid. 
Ρ. Hekman 
Nijmegen, 30 sept. 1982. 


